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Abbreviations
AA  arachidonic acid
AGES  Age Gender Extent 
AMES  Age Metastasis Extent Size
Bcl-2   B cell lymphoma gene-2
COX  cyclooxygenase
DAMES DNAploidy Age Metastasis Extent Size
EIA  Enzyme Immuno Assay
HUCH  Helsinki University Central Hospital
LNM  Lymph Node Metastases
MACIS  Metastasis Age Completens of resection Invasion Size
MMP  Matrix metalloproteinase
MRND  Modiﬁ ed Radical Neck Dissection
NCCN  National Comprehensive Cancer Network
NPA  Human papillary thyroid cancer cell line
NS-398  N-(2-Cyclohexyloxy-4-nitrophenyl)-Methanesulfonamide
PBS  Phosphate-buffered saline
PGE
2
  Prostaglandin E2
PMA  phorbol 12-myristate 13-acetate
PTC  Papillary Thyroid Cancer
PTEN  Phosphatase and tensin homolog on chromosome 10 
RAI  Radioactive iodine
RET   REaranged during Transfection
RT-PCR Real-time quantitative Polymerase Chain Reaction
SAG  Sex Age Grade
TBP  TATA-binding protein
TNM  Tumour Node Metastasis
TSH  Thyroid Stimulating Hormone
UICC  Union Internationale Contre le Cancer (International    
  Union Against Cancer)
VEGF  Vascular Endothelial Growth Factor
Abbreviations
52.
List of Original
Publications
This thesis is based on the following original publications, which are referred to 
in the text by their Roman numerals:
I Voutilainen PE, Siironen P, Franssila KO, Sivula A, Haapiainen RK, 
Haglund CH. AMES, MACIS and TNM prognostic classiﬁ cations in 
papillary thyroid carcinoma. Anticancer Research 2003;23(5b):4283-8.
II  Siironen P, Ristimäki A, Nordling S, Louhimo J, Haapiainen R,
Haglund C. Expression of COX-2 is increased with age in papillary 
thyroid cancer. Histopathology 2004;44(5):490-7.
III  Siironen P, Nordling S, Louhimo J, Haapiainen R, Haglund C.
Immunohistochemical expression of bcl-2, Ki-67, and p21 in papillary 
thyroid cancer; Ki-67 expression is increased in older patients. Tumor 
Biology 2005;26:50-56.
IV  Siironen P, Louhimo J, Nordling S, Ristimäki A, Mäenpää H, 
Haapiainen R, Haglund C. Prognostic factors in papillary thyroid 
cancer; An evaluation of 601 consecutive patients. Tumor Biology 
2005;26:57-64.
V  Siironen P, Ristimäki A, Narko K, Nordling S, Louhimo J, Andersson S, 
Haapiainen R, Haglund C. VEGF-C and COX-2 expression in papillary 
thyroid cancer. In manuscript. 
The original publications are reprinted with the permission of the copyright 
holders.
list of original publications
63.
Abstract
As age is the most important predictor of survival in papillary thyroid cancer 
(PTC), our interest was to compare young and older patients and to discover 
any possible association between increasing age and higher incidence of poor 
prognostic factors. Our hypothesis was that expression of selected tumour 
markers between young and older patients differs and that the same marker 
could identify the high-risk patients also among young patients. Our aim was to 
ﬁ nd a marker or set of markers to predict individual patient outcome better than 
do existing staging methods. 
We analyzed the medical records of consecutive patients who underwent surgery 
for papillary thyroid cancer at Helsinki University Central Hospital (HUCH) 
between 1957 and 1996 (n= 682). We compared AMES (Age-Metastasis-Extent-
Size), MACIS (Metastasis-Age-Completens of resection-Invasion-Size) and TNM 
(Tumour-Node-Metastasis) staging systems in predicting carcinoma-speciﬁ c 
mortality in 495 papillary thyroid carcinoma patients. For immunohistochemical 
studies, we retrospectively selected two patient groups. One included 108 patients 
selected by age (under 35 and over 55 years) to compare young and older PTC 
patients, and the other 36 matched pairs selected by tumour behaviour (aggressive 
versus completely recovered) to compare differently behaving tumours. We 
studied expression of the tissue markers COX-2, MMP-2, bcl-2, Ki-67, p21, and 
VEGF-C. Furthermore, we investigated by Real-time quantitative Polymerase 
Chain Reaction (RT-PCR) and Enzyme Immuno Assay (EIA) methods the 
relation of VEGF-C and of COX-2 expression in human papillary thyroid cancer 
cells (NPA). 
In predicting prognosis, TNM classiﬁ cation was more reliable than AMES or 
MACIS. 
abstract
7Age over 45 years, tumour size > 4 cm, extrathyroidal extension of tumour, nodal 
metastases, distant metastases, and stage IV disease signiﬁ cantly correlated with 
survival. 
Expression of COX-2, Ki-67, and VEGF-C was higher in older patients, and 
expression of these markers correlated with stage, but not with other clinical 
parameters or aggressive disease. Among the patients with positive lymph nodes, 
most tumours of older patients expressed VEGF-C, but most of those younger 
patients did not. Immunohistochemically, expression of COX-2 and VEGF-C 
correlated strongly with each other. In cell culture studies, both VEGF-C and 
COX-2 were induced by phorbol 12-myristate 13-acetate (PMA), but the selective 
COX-2 inhibitor N-(2-Cyclohexyloxy-4-nitrophenyl)-Methanesulfonamide (NS-
398) did not reduce VEGF-C expression. Thus, correlation of COX-2 and VEGF-
C was not so clear. 
Stromal expression of MMP-2 correlated with the extent of the primary tumour 
and with advanced stage, but not with aggressive disease. Expression of p21 was 
higher in tumours extending beyond the thyroid capsule and in larger tumours, 
but expression did not correlate with aggressive disease. Expression of Bcl-2 
correlated neither with clinical parameters nor aggressive disease. 
Most patients with papillary thyroid cancer can be cured if treated according to 
best clinical practice. In older patients, PTC is a more aggressive disease. Lymph 
node metastases (LNM) seemed to be predictive for distant metastases and death 
in older patients, but not at all for those younger. Unexpectedly, however, some 
young low-risk patients do suffer from aggressive disease. How to recognize these 
young patients is the problem. Although we found elevated expression of COX-2, 
VEGF-C, and Ki-67 in those older, these three markers did not predict patient 
outcome. Better understanding of differences in tumour biology in young and 
older patients may help us to select those young patients who display the tumour 
behaviour of older patients. 
Initial treatment and follow-up could be individualized according to age. Older 
lymph node-positive PTC patients may beneﬁ t from more radical lymph node 
dissection. These patients may also beneﬁ t from COX-2 selective inhibitors. 
abstract
84.
Introduction
Despite the generally indolent behaviour of papillary thyroid cancer, we need to 
identify patients who experience an unfavourable outcome. Currently, several 
risk-classiﬁ cation methods have been established to predict the prognosis of 
individual patient at the time of diagnosis, TNM classiﬁ cation being the most 
widely used prognostic scoring system for thyroid cancer (Hay et al. 1987, Cady 
and Rossi 1988, Pasieka et al. 1992, Akslen 1993, Hay et al. 1993, Noguchi 
et al. 1994, Sobin and Wittekind 1997). However, a small proportion of PTC 
patients and even those classiﬁ ed as low-risk can develop an aggressive disease, 
and consequently none of these classiﬁ cations can be considered completely 
reliable. 
To reduce the number of thyroid cancer recurrences, our aim was to ﬁ nd a marker 
or a set of markers to predict the outcome of an individual patient better than 
does TNM classiﬁ cation alone. Thus far, thyroglobulin is the only tumour marker 
being routinely used in PTC. The main use of thyroglobulin is to determine 
the effectiveness of thyroid cancer treatment and to monitor for recurrence, not 
to predict prognosis. With an ideal tumour marker, we could select high-risk 
patients for more aggressive therapy. These patients could probably beneﬁ t from 
more radical lymph node dissection and should also be under more intensive 
follow-up. 
Our hypothesis was that expression of selected tumour markers between young 
and older PTC patients differs. PTC is an atypical cancer in two ways; ﬁ rst, its 
aggressiveness increases signiﬁ cantly in older patients, and second, lymph node 
metastasis does not indicate poor survival, especially in young patients. It has 
been supposed that PTC is a biologically different disease depending on age (Cady 
introduction
91998). In young patients, PTC does not behave like normal cancers: Survival is 
excellent, and the cancer does not metastasize further than to the regional lymph 
nodes. In older patients, however, PTC behaves like other cancers: it metastasizes 
and may cause death. One present problem is that even though most young 
patients have a good prognosis, some of these low-risk patients suffer from early 
recurrence and even die of cancer. We assumed that if expression of a marker 
is altered in older patients, this marker could be helpful in selecting high-risk 
patients from the young patient group for more intensive therapy and follow-
up. 
In older patients, it has been suggested that tumours grow faster (Tubiana et al. 
1985), distant metastases occur more frequently (Bacourt et al. 1986, Samaan et 
al. 1992), and extracapsular extension of the primary tumour is more common 
(Samaan et al. 1992, Coburn and Wanebo 1995, Kurozumi et al. 1998). Changes 
in the cell-cycle and apoptosis, or in the signalling pathways controlling them, 
allow cancer cells to escape the normal control of cell proliferation and cell death 
(Evan and Vousden 2001). Changes in cell proliferation and death (bcl-2, Ki-67, 
p21) could possibly explain the different behaviour of PTC between young and 
older patients. Moreover, cancer cells` ability to invade and form fatal metastases 
(COX-2, MMP-2, VEGF-C) is the reason for cancer deaths seen in older patients. 
Thus, our interest was to study the expression of COX-2, MMP-2, VEGF-C, bcl-2, 
Ki-67, and p21 in PTC. 
introduction
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5.
Review of 
the Literature
Thyroid cancer is the most common endocrine cancer and accounts for 1% of 
cancer cases. Patients with thyroid cancer usually present with a solitary thyroid 
nodule. Of all thyroid nodules, only 5% are malignant. Of these, 80 to 95% are 
differentiated thyroid carcinomas (papillary and follicular), 5 to 10% medullary 
carcinomas, and the remaining 1 to 2% undifferentiated (anaplastic) thyroid 
carcinomas (Table 1). Medullary thyroid carcinoma arises from C cells, all other 
types from follicular cells (DeLellis et al. 2004). Among differentiated thyroid 
carcinomas, lymph node metastases are uncommon in follicular carcinoma 
(10%), in contrast to papillary carcinoma, in which lymph node metastases are a 
common ﬁ nding (30-40%) (Emerick et al. 1993, Gilliland et al. 1997). Moreover, 
distant metastases are more common in patients with follicular carcinoma 
(30%), and the tumours are larger in size (Emerick et al. 1993). Medullary 
thyroid carcinoma is hereditary in about 25% of cases and spreads to the lymph 
nodes earlier than do differentiated thyroid carcinomas. In contrast to papillary, 
follicular, and medullary thyroid carcinomas, anaplastic thyroid carcinoma is one 
of the most aggressive neoplasms in humans (Ain 1998). Prognosis is very poor 
and survival is measured in months, the median survival from diagnosis ranging 
from 3 to 7 months (McIver et al. 2001, Sugitani et al. 2001). A small proportion 
of patients enjoy long-term survival (Ain 1998, Nilsson et al. 1998). 
review of the literature
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Table 1. Thyroid cancer types, occurrence, peak onset ages, and 10-year survival rates 
(Gilliland et al. 1997, Hundahl et al. 1998, McIver et al. 2001). Sporadic medullary 
carcinoma occurs in older patients (40 to 60 years) in contrast to hereditary medullary 
carcinoma. 
5.1 Epidemiology
Papillary thyroid carcinoma is the most common malignant tumour of the 
thyroid gland, accounting for 70 to 80% of all thyroid cancers (Gilliland et al. 
1997, Hundahl et al. 1998). It is two to four times as frequent in women as in 
men (DeLellis et al. 2004). These tumours may arise at any age, but are most 
common between 30 and 50 years, with mean age at diagnosis being 45 to 50. In 
Finland, the incidence of papillary thyroid cancer has increased. According to the 
Finnish Cancer Registry (www.cancer.ﬁ ), the number of new thyroid cancer cases 
in 2003 was 374 (98 male, 276 female), which accounts for 1% of all cancers. In 
Finland, thyroid cancer is the 14th most common cancer in females. 
5.2 Aetiology
Oncogenes
The role of oncogenes in thyroid cancer is a subject of intense investigation; 
several genes have been implicated in the molecular carcinogenesis of PTC. 
The most commonly described genetic changes in PTC are the rearrangements of 
the RET (REarranged during Transfection) proto-oncogene (RET/PTC) (Santoro 
et al. 1992, Sugg et al. 1998) which is located in chromosome 10q11.2 (Myers et 
al. 1995). RET/PTC rearrangements are found in 20 to 30% of sporadic adult 
papillary carcinomas (Santoro et al. 1992, Bongarzone et al. 1998), and in 45 
to 60% of tumours from children and young adults (Bongarzone et al. 1996, 
Fenton et al. 2000). The RET/PTC rearrangements have been associated with 
review of the literature
Thyroid cancer type
Occurrence
(%)
Peak onset age
(years)
10-year 
survival
(%)
Papillary 70-80 30-50 93-98
Follicular 10-15 40-60 85-93
Medullary 5-10 40-60/ 30-50 75-80
Anaplastic 1-2 60-80 3-14
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young age and previous exposure to ionizing radiation (Kazakov et al. 1992). The 
reported frequency of RET-positive PTC cases in Chernobyl is 51 to 76%, which 
is higher than in most series of spontaneous thyroid cancers (Fugazzola et al. 
1995, Klugbauer et al. 1995, Thomas et al. 1999). The correlation between RET/
PTC rearrangements and the clinical outcome is obscure. It has been suggested 
that RET/PTC may be associated with greater likehood of metastatic spread and 
worse prognosis (Jhiang and Mazzaferri 1994, Sugg et al. 1996). 
The other known genetic changes occurring in papillary carcinoma are TRK 
rearrangements, RAS mutations, BRAF mutations, and p53 mutations. TRK 
gene chromosomal rearrangements are found in 10% of papillary carcinomas 
(Bongarzone et al. 1998, Musholt et al. 2000), RAS mutations in less than 10% 
(Namba et al. 1990, Hara et al. 1994, Ezzat et al. 1996), and BRAF mutations 
in up to 70% (Kimura et al. 2003, Nikiforova et al. 2003, Soares et al. 2003). In 
a study of Nikiforova et al. (2003), BRAF-positive patients were older and had 
a higher incidence of extrathyroidal extension. P53 gene mutations occur in 
many carcinomas (Hollstein et al. 1991). In thyroid carcinoma, p53 mutations 
are frequently found in anaplastic carcinoma, but rarely in papillary thyroid 
carcinoma (Ito et al. 1992, Donghi et al. 1993, Ho et al. 1996, Farid 2001). This 
suggests that the p53 mutations play an important role in progression from 
differentiated thyroid carcinomas to anaplastic carcinoma. 
Thyroid irradiation
Radiation exposure leads to increased risk for thyroid cancer (Kazakov et al. 
1992), but it does not affect the prognosis or the aggressiveness of the tumour. 
Irradiation during childhood has been associated with the greatest risk for 
acquiring papillary thyroid cancer. After the Chernobyl disaster, childhood 
thyroid carcinoma showed a great increase (up to 100-fold) in Belarus and 
Ukraine (Kazakov et al. 1992). 
Familial
The frequency of familial nonmedullary thyroid cancer has been shown to vary 
between 2.5 and 6.3% (Loh 1997). About 6% of PTC show a familial component 
(Lupoli et al. 1999). One gene has been identiﬁ ed, a phosphatase and tensin 
homolog on chromosome 10 (PTEN); germ line mutations have occurred in 80% 
of patients with Cowden syndrome (multiple hamartoma syndrome) (Liaw et al. 
1997, Marsh et al. 1998). Cowden´s syndrome is, however, associated more often 
with follicular thyroid cancer, and rarely with papillary thyroid cancer (DeLellis 
et al. 2004). Patients with familial adenomatous polyposis appear to have an 
increased incidence of papillary thyroid cancer (Cetta et al. 2000).
review of the literature
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5.3 Histology
Usual type. The typical papillary carcinoma is referred to as the usual type. The 
diagnosis of PTC is based on nuclear features which should be present in a 
signiﬁ cant proportion of the neoplasm (Vickery et al. 1985). Papillary architecture 
is not always present. Nuclei appear “optically clear” or resemble the eyes of the 
comic-strip character “Little Orphan Annie”. Grooves may also be evident in the 
nuclei, which result from folds in the nuclear membrane. The papillae of the 
usual PTC have ﬁ brovascular cores covered by cells with nuclei that overlap and 
appear to be “piled” one on the other. 
Most papillary carcinomas are of this usual type and about 25% belongs to 
histological variants (Carcangiu et al. 1985, Akslen and LiVolsi 2000). The 
most important variants are microcarcinoma, the follicular variant, the diffuse 
sclerosing variant, oncocytic variant (Hürthle cell PTC), the tall cell and the 
columnar cell variants. 
Variants of papillary carcinomas
Microcarcinoma. Microcarcinoma is a papillary carcinoma 1 cm or less in 
diameter. These lesions are of very low malignancy, and distant metastases are 
exceptionally rare. The indolent behaviour of these lesions is shown by their 
frequency as incidental ﬁ ndings in autopsy studies, being 6 to 7% in USA, 
Portugal, and Sweden (Sampson et al. 1974, Sobrinho-Simoes et al. 1979, 
Bondeson and Ljungberg 1984), 24% in Japan (Fukunaga and Yatani 1975), and 
35% in a study from Finland (Harach et al. 1985). 
Follicular variant. The follicular variant of PTC is the most common subtype 
of PTC after the usual type. It is composed of follicles and has characteristic 
papillary type nuclei (Chem and Rosai 1977). Thus, diagnosis of PTC is made 
when papillae are absent. These lesions behave biologically similarly to the usual 
type. In addition to common follicular variant, two other types of follicular variant 
have been described. The macrofollicular variant (Albores-Saavedra et al. 1991) is 
less aggressive and the diffuse follicular variant more aggressive than common 
follicular variant (Ivanova et al. 2002). The diffuse follicular variant occurs mainly 
in young females. In series of eight patients, all developed metastases in lungs, 
bones or both, two of them died of PTC (Sobrinho-Simoes et al. 1990). 
Diffuse sclerosing variant. This variant was initially described by Crile and Fisher 
in 1953. It occurs predominantly in young individuals and is characterized by 
diffuse involvement of one or both lobes, dense sclerosis, abundant psammoma 
bodies, typical papillary carcinoma elements, foci of squamous metaplastic 
change, and a patchy lymphocytic inﬁ ltrate (Vickery et al. 1985). Metastases both 
to cervical nodes and lungs are more frequent than in the usual type (Carcangiu 
and Bianchi 1989). 
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Oncocytic variant (Hürthle cell PTC). Oncocytic variant is characterized by the 
presence of oncocytes (also called oxyphilic cells), which are large polygonal cells 
with hyperchromatic nuclei and an eosinophilic granular cytoplasm (DeLellis et 
al. 2004). This oncocytic variant may have a papillary or follicular architecture. 
Diagnosis is based on the classical nuclear features of papillary thyroid carcinoma. 
It seems to behave in a fashion analogous to the usual type of papillary carcinoma 
(Berho and Suster 1997, Cheung et al. 2000, Ludvikova et al. 2001). 
Tall cell variant. Tall cell variant is deﬁ ned as PTC in which a minimum of 30% 
of the cells have a height at least twice their width, indicating a more aggressive 
growth pattern (Johnson et al. 1988). The tall cell variant is associated with a 
higher incidence of recurrence and mortality (Prendiville et al. 2000). It occurs 
more often in older patients (Ruter et al. 1997). 
Columnar cell variant. Thyroid tumours with columnar features were ﬁ rst 
described by Evans in 1986. They are rare, aggressive and have high mortality 
(Sobrinho-Simoes et al. 1988, Gaertner et al. 1995). The papillae are lined by tall 
columnar cells showing pseudostratiﬁ cation. The nuclei are elongated or oval, 
and are rich in chromatin, unlike the usual type. Columnar cell variant is an 
aggressive tumour associated with a fatal outcome. 
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5.4 Staging
Many staging systems have been developed to predict the prognosis of the PTC 
patient. These systems quantify various characteristics of the tumour and the 
patient. The essence of all staging methods is that age is a major factor that 
determines prognosis. Young patients rarely die of their disease. 
The most commonly used staging method is International Union Against Cancer 
(UICC) TNM classiﬁ cation (Sobin and Wittekind 2002). Other common staging 
methods are AGES, MACIS, AMES, DAMES and SAG. The Mayo clinic described 
a prognostic scoring system based on patient age, tumour grade, extent, and size 
(AGES) (Hay et al. 1987) and a model including ﬁ ve variables abbreviated by 
metastasis, age, completeness of resection, invasion, and size (MACIS) (Hay et 
al. 1993). Cady et al. described a completely clinical classiﬁ cation based on age 
of patient, presence of distant metastases, extent and size of the tumour (AMES) 
(Cady and Rossi 1988). Pasieka et al. modiﬁ ed AMES risk-group classiﬁ cation 
to include DNA ploidy with AMES (DAMES) (Pasieka et al. 1992). Akslen et al. 
demonstrated that histologic grade is a strong and independent prognostic factor 
and introduced SAG score (sex, age, and grade) (Akslen 1993). These staging 
methods are described below. 
TNM. TNM classiﬁ es all patients under 45 years in a low-risk category regardless 
of whether lymph nodes are involved, some of the tumour is not removed, or 
even regardless of distant metastases. In our study, we used TNM staging 1997 
(Sobin and Wittekind 1997). 
A new TNM classiﬁ cation of malignant tumours has been published (Sobin and 
Wittekind 2002). Compared to the 1997 5th edition some changes have been made 
in thyroid carcinoma classiﬁ cation. Major changes are that T1 includes tumours 
sized 2 cm or less and that T3 includes tumours with minimal extrathyroid 
extension. 
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Table 2 UICC age-related TNM staging (1997) for papillary and follicular thyroid 
carcinoma.
Stage Age <45 year Age >/=45 year
I T1-4N0,1M0 T1N0M0
II T1-4N0,1M1 T2-3N0M0
III T4N0M0 or
T1-4N1M0
IV T1-4N0,1M1
T1 ≤ 1cm
T2 > 1cm, ≤ 4cm
T3 > 4cm
T4 Extrathyroidal
N1 Positive neck lymph node
M1 Positive distant metastasis
AGES (Hay et al. 1987, based on 860 patients). The prognostic score (PS) was 
generated by regression analysis. PS = 0.05 x age in years (if age 40 or more) or 
0 (if less than 40), +1 (if grade 2) or +3 (if grade 3 or 4), +1 (if extrathyroid) or +3 
(if distant spread), +0.2 x tumour size (maximun diameter in centimetres). The 
860 patients were divided into four risk groups according to the score. Group 1 
(86%) had scores 0 to 3.99, and had 25-year mortality from cancer of 2%. Group 
2 (7%) had scores 4 to 4.99 and 25-year mortality of 24%. Groups 3 and 4, with 
scores 5 to 5.99 and 6+, had 25-year mortality rates of 49% and 93% respectively. 
Patients in Group 1 were considered to be at “minimal” risk of cancer mortality.
AMES (Cady and Rossi 1988, based on 821 patients). The risk-group deﬁ nition 
is completely clinical. It can be used at the operating table to select conservative 
surgical procedures for low-risk patients. Cady and Rossi offered a multifactorial 
system for the identiﬁ cation of low-risk patients who made up 89.4% of all 
patients seen between 1961 and 1980 and who had a death rate of only 1.8%. 
The high-risk group constitutes 11% of cases but carries a 46% mortality rate. 
Low-risk group: A. All younger patients without distant metastases (men <41 
years; women <51 years). B. All patients with: 1. intrathyroidal papillary cancer, 
and 2. primary cancers <5 cm in diameter, and 3. no distant metastases. High-
risk group: A. All patients with distant metastases. B. All older patients with: 1. 
extrathyroidal papillary cancer, and 2. primary cancers 5 cm in diameter or larger 
regardless of extent of disease.
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DAMES (Pasieka et al. 1992, based on 73 patients). Patients with euploid tumours 
that were AMES low risk were considered to be DAMES low risk; patients with 
euploid tumours that were AMES high risk became intermediate risk, and 
patients with aneuploid tumours that were AMES high risk became DAMES 
high risk. Three patients were in the DAMES high-risk group. Distant metastases 
developed in all three, who died from thyroid cancer within 24 months. In the 
low-risk group (n=48), distant metastases developed in four patients, no death 
occurred from cancer. In the intermediate group (n= 22), 12 had residual or 
recurrent disease, or distant metastases, with one death from cancer.
MACIS (Hay et al. 1993, based on 1779 patients). The prognostic score in the 
MACIS model = 3.1 (if aged or = 40 years), + 0.3 x tumour size (in centimetres), +1 
(if incompletely resected), +1 (if locally invasive), +3 (if distant metastases present). 
Twenty-year cause-speciﬁ c survival rates for patients with MACIS less than 6, 6 
to 6.99, 7 to 7.99, and 8+ were 99%, 89%, 56%, and 24%, respectively.
SAG (Akslen et al. 1993, based on 263 patients). The SAG score represents the 
sum of the following features: sex (female, 0; male 1), age (younger than 70 
years, 0; 70 and older, 1), grade (histologic grade 1, 0; histologic grade 2, 1). 
Histologic grade, based on absence or presence of the three microscopic key 
features: vascular invasion, marked nuclear atypia, and tumour necrosis (VAN 
features). Grade 1 (low grade) was recorded when none of the VAN features were 
present, Grade 2 (high grade), was recorded when any of the VAN features were 
present. Three patient groups at different risk for cancer death emerged: SAG I-
III (SAG I: score 0; SAG II: score 1; SAG III: score 2-3). Estimated risk for thyroid 
cancer death in 15 years in three groups were: SAG I (n= 97) 1.7%, SAG II (n= 55) 
12.0%, and SAG III (n= 21) 61.0%. 
review of the literature
18
5.5 Treatment
Patients with thyroid cancer should be managed by regionally designed 
multidisciplinary teams comprising a surgeon, endocrinologist, and oncologist 
with the support of a pathologist, medical physicist, biochemist, radiologist, and 
specialist nurse (Kendall-Taylor 2003). 
Thyroidectomy. The balance between complications and extent of surgery 
has been an issue in whether thyroidectomy or a more conservative unilateral 
approach should be recommended for low-risk papillary cancers. The most 
common signiﬁ cant complications of thyroid surgery are permanent recurrent 
laryngeal nerve palsy and permanent hypoparathyroidism. The disadvantage 
of remaining thyroid tissue after surgery is an argument against conservative 
treatment, because remnant thyroid tissue makes follow-up difﬁ cult. In 
addition, performing lobectomy alone results in a 5 to 10% recurrence rate in 
the contralateral thyroid lobe, higher tumour recurrence, and higher incidence 
of distant metastases (Massin et al. 1984, Samaan et al. 1985, Hay et al. 1987). 
Complication rates have improved in the hands of experienced surgeons, and 
the main argument against extensive surgery seems less important. A study of 
5860 patients in the USA found that surgeons who performed more than 100 
thyroidectomies annually had the lowest overall complication rates (4.3%) (Sosa 
et al. 1998). In that study, those who performed less than 10 cases annually 
had 4-fold higher complication rates. The rates of permanent hoarseness and 
hypoparathyroidism are much lower than immediately after surgery. A work by 
Pattou et al. (1998) found hypocalcemia in 5.4% of patients immediately after 
surgery, but a year later in only 0.5%. A study of seven surgical series found that 
after total thyroidectomy the average rates of permanent laryngeal nerve injury 
and hypoparathyroidism were 3% and 2.6% (Udelsman et al. 1996). 
If the diagnosis of cancer is clear at the time of surgery, most clinicians in the 
USA and Europe agree that total or near-total thyroidectomy is the treatment of 
choice (DeGroot et al. 1994, Solomon et al. 1996, Sherman et al. 1998, Mazzaferri 
1999, Cailleux et al. 2000, Hundahl et al. 2000). Lobectomy alone has shown 
to be adequate for papillary microcarcinoma (< 1cm) discovered after surgery 
for benign disease (Mazzaferri and Jhiang 1994, Baudin et al. 1998). Total 
thyroidectomy is, however, the optimal treatment for microcarcinoma patients 
with multiple foci (Baudin et al. 1998). Based on these recommendations, at 
Helsinki University Central Hospital all preoperatively diagnosed PTC patients 
undergo total thyroidectomy. If occult PTC (one focus) is diagnosed after goiter 
surgery, lobectomy is believed to be sufﬁ cient. 
Lymph node dissection. Another issue is the extent of lymph node dissection. As 
the impact of lymph node metastasis is in dispute, so is also the extent of lymph 
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node dissection. 
Most surgeons agree that prophylactic neck dissection is not routinely necessary, 
as postoperative radioactive iodine (RAI) ablation destroys remnant thyroid 
tissue and possible micrometastasis. Another arguments against lymph node 
dissection, is that lymph node metastases do not affect survival (McConahey 
et al. 1986, Shah et al. 1992). If the patient has palpable nodes, some authors 
recommend selective resection for involved nodes only (Mazzaferri and Young 
1981, Hay et al. 1998), and others recommend modiﬁ ed radical neck dissection 
(MRND) (McGregor et al. 1985, McHenry et al. 1991, Simon et al. 1996, Mann 
and Buhr 1998, Sivanandan and Soo 2001). During recent years, however, 
consensus is emerging that compartment-oriented neck dissection minimizes 
neck recurrences and is superior to a node picking procedure (in which only the 
grossly abnormal lymph nodes are excised) (Sherman et al. 2005). The National 
Comprehensive Cancer Network (NCCN) recommends central neck dissection 
(level VI) and lateral neck dissection (levels II-V) for lymph node-positive PTC 
(Sherman et al. 2005). 
In Japan, the standard practice for papillary thyroid carcinoma is subtotal 
thyroidectomy with modiﬁ ed radical neck dissection of the affected side 
(Yamashita et al. 1998, Uchino et al. 2004). Japanese surgeons recommend 
prophylactic systemic cervical node dissection, as they have found that this 
improves prognosis (Noguchi et al. 1998). The presence of gross nodal metastases 
has also been shown to be an important risk factor for survival (Yamashita et al. 
1998). Japanese surgeons do not, however, use RAI ablation routinely because of 
rigid regulations for the use of radioisotopes in Japan (Yamashita et al. 1998). 
Some centres, including our own, at present continue to do node picking procedure. 
At our department, if suspicion or evidence of lymph node involvement (biopsy, 
ultrasound, or at operation) exists, pathological lymph nodes are removed. This 
may change in future as more information becomes available.
Modiﬁ ed radical neck dissection. MRND is deﬁ ned as removing all of the 
lymphatic tissue at levels I-V and preserving the sternocleidomastoid muscle, 
internal jugular vein, and spinal accessory nerve (Khatri and Loree 2002).
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Figure 1 Cervical regional lymph nodes (level I-VI). 
RAI ablation. Total thyroidectomy is followed by radioactive iodine ablation. 
Radioiodine therapy reduces local recurrence and improves survival (Mazzaferri 
and Kloos 2001). Thyroid cells are unique among all cells of the human body as 
they have the ability to absorb iodine. Iodine is a key component of the hormone 
thyroxin. Thyroid cells combine iodine and the amino acid tyrosine 
to make thyroxin. Every cell in the body depends upon thyroid 
hormones for regulation of its metabolism. Thyroid cells will absorb 
and concentrate also radioactive iodine, and the radioactivity destroys the cell. 
Because papillary and follicular thyroid cancer cells retain this ability to absorb 
iodine, radioiodine thus destroys any remaining normal thyroid tissue and occult 
microscopic carcinoma. This means that even metastatic disease in most cases 
will be treatable. 
Treatment of local recurrences and distant metastases. Surgery is the ﬁ rst 
choice for neck recurrences, and regional recurrences are removed surgically if 
possible. After surgery, or if surgery is not suitable, local and regional recurrences 
detected by 131I whole-body scans are treated with 131I ablation with good results. 
External radiotherapy is recommend for those non-operable recurrences that 
do not concentrate 131I, and recommended when surgery is done repeatedly 
(Schlumberger 1998, Sherman et al. 2005). 
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For metastatic disease, surgery, 131I ablation, and external radiotherapy are 
recommended depending on the site of metastases and radioiodine uptake 
(Niederle et al. 1986, Schlumberger et al. 1986, Sherman et al. 2005). Surgery 
is recommended for all solitary metastases. Radioiodine is recommended for 
disseminated tumours that concentrate 131I and external radiotherapy if the 
tumour does not concentrate 131I. For skeletal metastases, external radiotherapy 
is the ﬁ rst choice. 
Thyroxine. PTC responds to thyroid stimulating hormone (TSH) secreted 
by the pituitary. Thus a high dose of exogenous thyroid hormone, thyroxine, 
postoperatively results in decreased TSH levels and a lower impulse for any 
remaining cancer cells to grow. 
Follow-up. Follow-up is based on measuring serum thyroglobulin levels. 
Thyroglobulin is a glycoprotein produced by normal or neoplastic follicular cells. 
It should not be detectable in the circulation, if the patient has undergone total 
thyroid ablation. Measurable thyroglobulin in the absence of antibodies indicate 
the presence of persistent or recurrent disease. 
5.6 Prognosis
The vast majority of patients can expect to be cured if treated according to best 
practice. In series of over 15 000 patients, 10-year survival was 98% (Gilliland et 
al. 1997), and in a series of 53 000 patients, 93% (Hundahl et al. 1998). Despite 
the good prognosis, local or regional tumour recurrences occur in 5 to 20% of 
patients with PTC, depending on initial treatment and other prognostic variables. 
At the time of diagnosis, distant metastases are very uncommon, but during 
follow up 6 to 11% of PTC patients develop distant metastases (Table 11). Although 
patients may live for long time with distant metastases, this does signiﬁ cantly 
worsen prognosis. About one-third of patents with distant metastases survive 
for 10 years (Hoie et al. 1988, Ruegemer et al. 1988, Schlumberger et al. 1996). 
Age is important for both predicting development of distant metastases and for 
inﬂ uencing long-term survival. 
Age
Age is the most important prognostic variable. Unlike other types of cancer, the 
prognosis of papillary thyroid cancer depends largely on the age. Young people 
rarely die of their disease regardless of lymph node metastases or even distant 
metastases. For older patients, however, prognostic factors play a signiﬁ cant role 
in long-term disease-free survival. Ten-year survival for patients younger than 20 
has been 99%, compared to 86% for patients 70 years and older (Gilliland et al. 
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1997). One study showed a clear cut age-related decrement in survival: 10-year 
survival was 92% in patients aged 21 to 50, 77% in those 51 to 70, and 48% in 
those over 71 (Coburn and Wanebo 1995). 
The age at which a patient´s prognosis becomes poor has been a matter of 
debate. The cut-off age for poor prognosis has shown to be between 40 and 70 
in prognostic staging classiﬁ cations (AGES 40; AMES 41 in men, 51 in women; 
MACIS 40; SAG 70; TNM 45) (Hay et al. 1987, Cady and Rossi 1988, Akslen 
1993, Hay et al. 1993, Sobin and Wittekind 1997). The UICC TNM system 
classiﬁ es all patients under 45 in the low-risk category independent of tumour 
size, extent of tumour, lymph node metastases, and distant metastases (Sobin 
and Wittekind 1997). All these cut-off ages are estimated. There seems to be 
“a grey area” between 40 and 70; patients over 70 have a poorer prognosis, but 
these grey area patients perhaps not.
Older PTC patients may represent a biologically distinct group. Relation of old 
age to other poor variables is uncertain. Coburn and Wanebo (n=382) showed 
that survival decreases and recurrence rates increase with age (Coburn and 
Wanebo 1995). They demonstrated that old patients show more high-risk factors 
such as extracapsular extension and vascular invasion. The interval between 
primary treatment and relapse was shorter in older patients, and authors suggest 
that tumours grow faster in patients over 45 (Tubiana et al. 1985). Bacourt et al. 
(1986) showed that large tumours, distant metastases and poorly differentiated 
forms occur mainly after 40. Samaan et al. (1992) found that the elderly more 
often have soft tissue involvement and bone metastases. Kurozumi et al. (1998) 
reported age to be related to extrathyroidal invasion. Thus it seems that older 
PTC patients have more pathological risk-factors, showing their tumours to be 
more aggressive. 
Tumour size
Increasing tumour size is an accepted factor in poor prognosis (DeGroot et al. 
1990, Akslen 1993, Hay et al. 1993). Survival is shorter, if the tumour is over 4 
cm in diameter (Shaha et al. 1994). Furthermore, lymph node metastases are 
more frequent in patients with larger tumours (Gimm et al. 1998). 
Multifocality
PTC has been shown to be multicentric in 20 to 80% of patients (Schlumberger 
1998), the high variation probably reﬂ ecting the thoroughness of the pathologist. 
A few authors demonstrate multifocality as a strong factor for poor prognosis 
(Carcangiu et al. 1985, Mazzaferri and Jhiang 1994). In cases of microcarcinoma, 
the number of histologic foci has been shown to inﬂ uence recurrence (Baudin 
et al. 1998). 
Extent of tumour
Extrathyroid extension of the tumour has adverse effect on prognosis (Carcangiu 
et al. 1985, McConahey et al. 1986). Approximately one-third of patients who die 
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of PTC die of local disease (McConahey et al. 1986). Locally invasive papillary 
tumours are associated with risk for development of postoperative metastasis 
in cervical lymph nodes, risk for local recurrence, risk for development of 
postoperative distant metastases, and mortality (McConahey et al. 1986). Control 
of locally invasive tumour is therefore important. 
The most important factor from the surgical standpoint is extrathyroidal extension 
of the tumour. Radical resection of aerodigestive structures is not believed to be 
necessary, because conservative surgery for invasive PTC has produced similar 
survival rates (McCaffrey et al. 1994, Czaja and McCaffrey 1997). In cases of 
gross intraluminal extension, life-threatening complications should be avoided 
by sacriﬁ cing aerodigestive tract structures (McCaffrey et al. 1994). In cases of 
minimal invasion of the tracheal cartilage, shaving tumour off the laryngotracheal 
structures is recommended. The goal of treatment is complete gross tumour 
removal with maximal preservation of function (Patel and Shaha 2005).
As for the role of age in the outcome after incomplete resection, the ﬁ ndings 
are contradictory. Older patients have a higher risk of death if the cancer is not 
grossly completely resected (Rossi et al. 1988). Other authors have, however, 
shown that among patients over 45, incomplete excision of tumour did not affect 
survival, as it did in younger patients (Andersen et al. 1995). They speculated 
that this could be due to the more aggressive course of the disease in these older 
patients. 
Male gender
The inﬂ uence of male gender for prognosis is a matter of controversy. Some 
studies have demonstrated an independent inﬂ uence of gender on probability 
of relapse and survival (Byar et al. 1979, Tubiana et al. 1985, Akslen 1993). The 
majority of studies reveal, however, that gender is not an important prognostic 
factor (Hay et al. 1987, Simpson et al. 1987, Hay et al. 1993). 
Histology
The diffuse sclerosing variant, tall cell variant, and columnar cell variant are 
more aggressive than the usual type. The diffuse sclerosing variant exhibits a 
greater incidence of lymph node metastases and lung metastases (Carcangiu and 
Bianchi 1989, Soares et al. 1989). The tall cell variant can invade blood vessels 
and metastasize via the blood stream as opposed to the usual variety of papillary 
carcinoma which spreads via the lymphatics rather than hematogenously 
(Prendiville et al. 2000). The columnar cell variant of thyroid papillary carcinoma 
is an aggressive tumour associated with widespread dissemination and a fatal 
outcome (Sobrinho-Simoes et al. 1988, Gaertner et al. 1995). 
The prognostic value of histologic grade (nuclear atypia, tumour necrosis, and 
vascular invasion) has been superior when compared to histologic subclassiﬁ cation 
(Akslen and LiVolsi 2000). In one series of 128 PTC patients, each histologic 
subtype appeared in only a few cases, making ﬁ rm conclusions difﬁ cult (Akslen 
and LiVolsi 2000). In one series of 401 patients, patients with extrathyroidal 
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vascular invasion had a higher incidence of distant metastases at diagnosis (40% 
vs. 4%), and patients with intrathyroidal vascular invasion were more likely to 
develop distant recurrence (20% vs. 3%) (Gardner et al. 2000). 
PTC can transform to anaplastic thyroid carcinoma (Harada et al. 1977). Anaplastic 
carcinoma is rare, representing 1 to 2% of thyroid neoplasms, but it accounts for 
nearly half of all cases of mortality associated with thyroid cancer (Giuffrida and 
Gharib 2000). Approximately half of patients with anaplastic thyroid carcinoma 
have a history of nodular goiter or differentiated thyroid carcinoma (McIver et 
al. 2001). Poorly differentiated thyroid carcinoma occupies both morphologically 
and behaviourally an intermediate position between differentiated and anaplastic 
thyroid carcinomas (Sakamoto et al. 1983, Papotti et al. 1993), and some of these 
tumours appear to arise also from pre-existing PTC (DeLellis et al. 2004). The 
characteristic histology includes the presence of a solid pattern or a trabecular 
or scirrhous pattern or both (Sakamoto et al. 1983). The mean 5-year survival is 
about 50% (Sakamoto et al. 1983, DeLellis et al. 2004). 
Lymph node metastases 
The prognostic signiﬁ cance of lymph node metastases is in dispute. Primary 
lymph node metastases are present in approximately 30 to 40% of adult patients, 
and microscopic involvement of lymph nodes in as many as 80 to 90% of the 
cases (Gilliland et al. 1997, Noguchi et al. 1998). The lymph node metastases are 
more common among young patients whose prognosis is excellent. Many authors 
have reported that lymph node metastases are associated with an increased rate 
of locoregional recurrence of disease, but not with survival (Simpson et al. 1987, 
DeGroot et al. 1990, McHenry et al. 1991, Lin et al. 1999, Beasley et al. 2002). 
Some authors have, however, shown that in older patients, LNM have an adverse 
effect on survival (Harwood et al. 1978, Tubiana et al. 1985, Mazzaferri and 
Jhiang 1994, Passler et al. 2004). Cady et al. (1998) suggest that in young PTC 
patients, metastatic cells in regional lymph nodes do not have the capacity to 
grow in other organs. This hypothesis could explain the differing inﬂ uence of 
lymph node metastases in older and young PTC patients. 
Distant metastases
At presentation, distant metastases are very uncommon (Mazzaferri et al. 1977), 
but during follow up 6 to 11% of PTC patients develop them (Table 11). Distant 
metastases can have a serious impact on survival. Age at diagnosis of distant 
metastases is the most important factor affecting mortality (Ruegemer et al. 
1988). The overall 10-year survival rate of patients with distant metastasis is 25 to 
35% (Hoie et al. 1988, Ruegemer et al. 1988, Schlumberger et al. 1996). In PTC, 
it is, however, possible to cure distant metastases as, 131I can destroy metastases, 
which take up iodine. 
The lungs are the most common site of distant metastases (70-80%), 
and pulmonary involvement is usually micronodular (Samaan et al. 1985, 
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Schlumberger et al. 1986, Dinneen et al. 1995). Second in order are bone 
metastases seen in 0.7 to 2% of PTC patients (Hoie et al. 1988, Marcocci et al. 
1989, Dinneen et al. 1995, Zettinig et al. 2002). The site of bone metastases is 
important for prognosis; metastasis to long bones has a worse prognosis than 
metastasis to the skull (Schlumberger et al. 1986). Mediastinium, brain, adrenal, 
skin, or liver are extremely rare sites for metastases. 
Numerous studies have reported that patients with 131I-accumulating metastases 
have far better prognosis than patients lacking such uptake (Samaan et al. 1985, 
Schlumberger et al. 1986, Hoie et al. 1988). Young patients with lung metastases 
that take up radioiodine have the most favourable prognosis (Dinneen et al. 
1995, Schlumberger et al. 1996). In work by Pacini et al. (1994), micronodular 
diffuse lung metastases revealed by whole body scan without radiographic 
changes had the greatest chance of favourable response to radioactive iodine 
with complete response in most cases. Death from distant metastases is higher 
if lung metastases are macronodular and detectable by chest radiographs, if bone 
metastases are multiple, and if metastases to both lung and bone are present 
(Pacini et al. 1994). The occurrence of bone metastases signiﬁ cantly worsens 
survival, as bone metastases have a lower capacity to absorb radioiodine. 
Recurrences
Local or regional tumour recurrences occur in 5 to 20% of patients with PTC 
(Schlumberger 1998), with a tendency to occur early. In work by Grant et al. 
(1988), risk was greatest within the ﬁ rst 5 years after the initial operation, and 
in work by Coburn et al. (1994), approximately 50% of the recurrences occurred 
less than 2 years after initial treatment. However, recurrence of disease may 
emerge many years after primary diagnosis, even as late as 41 years after the 
initial treatment (Schlumberger et al. 1986). Patients whose metastases appear 
within 5 years of treatment and those who have multiple sites of metastasis have a 
poorer prognosis (Wood et al. 1989). Moreover, younger age at primary operation 
or reoperation has been associated with a better prognosis (Voutilainen et al. 
2001, Uruno et al. 2004). Voutilainen et al. (2001) showed that the prognosis 
for patients under 45 after recurrence was almost parallel to that of the normal 
reference population. 
Some of the metastases are related to incomplete initial treatment, and others 
indicate an aggressive primary tumour (Schlumberger 1998). Treatment may 
be as important as tumour biology in predicting tumour recurrence. In series of 
72 patients, reoperation was judged to have been preventable in 41 (57%) due to 
inadequate preoperative imaging, incomplete initial surgery, or absence of TSH 
suppression or due to all of these factors (Kouvaraki et al. 2004). 
Cause of death
As age increases, risk of death from PTC also increases. In patients under 
45, death from PTC is very uncommon. The cause of death in PTC is usually 
distant metastases, often lung metastases causing respiratory insufﬁ ciency or 
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compression of the great vessels. Local disease may cause massive haemorrhage 
from the major vessels of the neck or direct compression or invasion of the 
trachea (Smith et al. 1988, Kitamura et al. 1999). Patients who die of papillary 
thyroid cancer are usually over 45 at diagnosis, and have lymph node metastases, 
extrathyroid extension of tumour, or distant metastases (Ruegemer et al. 1988, 
Beasley et al. 2001).
Treatment
Adequate surgical treatment and radioactive iodine therapy for papillary thyroid 
cancer have improved long-term outcome, both in terms of recurrence and 
cancer death (Mazzaferri and Jhiang 1994). Time of primary operation is also 
important. Patients who die of PTC have had a longer delay of treatment than 
those who survived (18 months vs. 4 months) (Mazzaferri and Jhiang 1994). 
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5.7 Tumour markers in PTC
Tumour markers, usually proteins, can be detected in a solid tumour, in 
circulating tumour cells in peripheral blood, in lymph nodes, in bone marrow,or 
in other body ﬂ uids (ascites, urine, or stool). They are produced by the body in 
response to cancer growth or by the cancer tissue itself. Tumour markers can be 
used to screen a healthy population or a high-risk population for the presence of 
cancer, to make a diagnosis of cancer, to determine the prognosis of the patient, 
or to monitor the course in a patient during follow-up. The ideal tumour marker 
is speciﬁ c for the cancer for which it is testing, is not presented in any other 
conditions, and the concentration changes with the amount of malignant tissue 
present. 
Several studies have investigated tumour markers in papillary thyroid cancer, 
and some studies have reported them as promising for predicting prognosis, 
but no guaranteed markers for PTC have been established. At present, in PTC, 
thyroglobulin is the only tumour marker being routinely used. It is not useful as 
a diagnostic or prognostic marker. The main use of thyroglobulin is to determine 
the effectiveness of thyroid cancer treatment and to screen for recurrence. 
TUMOURIGENESIS
Tumourigenesis is a multistep process leading to progressive transformation 
of normal cells into cancer cells. During this process, cells lose their normal 
ability to sense and repair DNA damage and to regulate cell cycle progression 
and apoptosis. They acquire abnormal patterns of growth- signalling, abnormal 
angiogenesis, and abnormal invasive growth. 
Ki-67: proliferation
The Ki-67 antibody was named after its site of production in Kiel, Germany, and 
because the clone producing the antibody was grown in the 67th well of a 96-well 
microtitre plate (Gerdes et al. 1983). It recognizes an antigen which is associated 
with the cell nucleus and is expressed in all phases of the cell cycle except G0, 
with expression associated with tumour grade and number of mitoses (Gerdes 
et al. 1984). The proportion of proliferating cells is important for predicting the 
growth potential and aggressiveness of the tumour. The proliferation marker Ki-
67 is a prognostic marker in various cancers, with aggressive tumours displaying 
high expression (Brown and Gatter 1990, Endl and Gerdes 2000). 
Ki-67 and thyroid. Most authors have demonstrated low Ki-67 expression in 
differentiated thyroid carcinomas, but higher expression in those undifferentiated 
(Wallin et al. 1992, Katoh et al. 1995, Basolo et al. 1997, Okayasu et al. 1998, 
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Tallini et al. 1999, Yoshida et al. 1999, Saiz et al. 2002). In differentiated thyroid 
cancers, the percentage of positive cells has varied between 0.2 and 3 (Wallin 
et al. 1992, Basolo et al. 1997) and in the undifferentiated between 33 and 52 
(Katoh et al. 1995, Basolo et al. 1997). Sugitani et al. (1998) found that in a small 
group of PTC microcarcinoma patients, Ki-67 expression was higher in those 
with lymph node metastases and with noncapsulated tumours, and moreover, 
patients who died of cancer showed the highest Ki-67 expression. Others have 
found no correlation with clinical parameters (Katoh et al. 1995, Tallini et al. 
1999). 
p21: growth inhibition
Cyclin-dependent kinases (CDKs) make up a large family of proteins that function 
in a variety of key regulatory pathways including control over the cell cycle. 
Uncontrolled CDK activity is often the cause of human cancer. p21 (also known 
as Cip1, WAF1, SD11) is a cyclin-dependent kinase inhibitor transcriptionally 
activated by p53 in response to DNA damage. It is believed that wild-type (non-
mutant) p53 activates the production of p21. Wild-type p53 is not detectable, as 
it is degraded rapidly; however, after mutation, the half-life of p53 is prolonged, 
making immunohistochemical detection possible. The most common genetic 
change in human cancers is p53 mutation (Hollstein et al. 1991), and also p53-
independent pathways have been proposed (Parker et al. 1995). The ﬁ rst CDKI 
to be isolated was p21 (Xiong et al. 1992, el-Deiry et al. 1993, Harper et al. 1993). 
It is a proliferation inhibitor and plays an important role in preventing tumour 
development. In addition, p21 also acts as an inhibitor of apoptosis, counteracting 
its tumour-suppressive functions. Its expression is commonly altered in human 
tumours (Thor et al. 1984, Viola et al. 1985, Viola et al. 1986, Gomyo et al. 1997, 
Lu et al. 1998, Natsugoe et al. 1999, Shoji et al. 2002), and it has been associated 
with good prognosis in oesophageal, uterine, gastric, and pulmonary cancer 
(Gomyo et al. 1997, Lu et al. 1998, Natsugoe et al. 1999, Shoji et al. 2002) and 
with poor prognosis in breast cancer (Barbareschi et al. 1996). 
p21 and the thyroid. Many researchers have demonstrated that p21 plays no 
signiﬁ cant role in regulating the progression of thyroid carcinoma (Johnson et 
al. 1987, Mizukami et al. 1995, Ito et al. 1996). Some authors have, however, 
shown that p21 associates with clinical parameters in PTC (Basolo et al. 1994, 
Akslen and Varhaug 1995, Okayasu et al. 1998). In a study by Akslen and 
Varhaug (1995), expression of p21 protein was increased in PTC patients with 
lymph node metastases, but no signiﬁ cant association appeared between p21 
protein immunostaining and patient survival. Other researchers showed that 
p21 correlates with tumour aggressiveness in PTC, because its expression 
was signiﬁ cantly higher in fatal cases (Basolo et al. 1994). Anaplastic thyroid 
carcinomas and poorly differentiated papillary carcinomas show higher 
immunostaining than do well-differentiated PTCs (Okayasu et al. 1998). Thus, 
thyroid and breast cancer have revealed an association between over-expression of 
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p21 and bad outcome (Basolo et al. 1994, Akslen and Varhaug 1995, Barbareschi 
et al. 1996, Okayasu et al. 1998), in contrast to most other human tumours, in 
which over-expression of p21 is associated with good outcome (Gomyo et al. 1997, 
Lu et al. 1998, Natsugoe et al. 1999, Shoji et al. 2002). Differing patterns of p21 
expression in various cancers might be explained by the differing mechanisms 
regulating cell proliferation and apoptosis in differing epithelial systems (el-
Deiry et al. 1995). Expression of p21 is regulated by p53, but acts also via p53-
independent pathways (Michieli et al. 1994). In PTC, p53 mutation is rare, as it 
is in breast cancer (Steele et al. 1998). 
Bcl-2: apoptosis
Bcl-2 (B cell lymphoma gene-2) (Tsujimoto et al. 1984) oncoprotein, localized in 
the mitochondria, prolongs cell survival by inhibiting apoptosis (Hockenbery et 
al. 1990). Its over-expression is classically associated with malignant lymphomas 
and poor prognosis (Yunis et al. 1989), but its expression is also associated 
with good prognosis; thus, the precise mechanism of bcl-2 remains unknown. 
In addition to lymphoma, over-expression associates with poor prognosis in 
prostate and uterine cancer (Saegusa et al. 1995, Bubendorf et al. 1996), and 
in contrast, with good prognosis in ovarian, breast, oesophageal, and lung 
cancer, and in melanoma (Pezzella et al. 1993, Joensuu et al. 1994, Ofner et al. 
1995, Tron et al. 1995, Herod et al. 1996, Ohbu et al. 1997, Martin et al. 2003). 
Differing roles of bcl-2 in various neoplasia could be explained by tissue-speciﬁ c 
expression of bcl-2-binding proteins which determine the functional activity of 
bcl-2 (Boise et al. 1993). Moreover, it has been speculated that bcl-2 may retard 
the rate of proliferation in solid tumours, resulting in slow-growing tumours 
with a favourable outcome.
Bcl-2 and thyroid. Cytoplasmic bcl-2 staining is seen in normal thyroid 
epithelium. In thyroid carcinomas, bcl-2 expression correlates with degree of cell 
differentiation (Pilotti et al. 1994, Pollina et al. 1996, Moore et al. 1998, Puglisi 
et al. 2000). Bcl-2 appears to be associated with less aggressive behaviour as well 
differentiated, and poorly differentiated thyroid tumours express bcl-2; in cases 
of undifferentiated carcinomas, however, its expression is low. No correlation 
between bcl-2 and prognostic factors has appeared in papillary thyroid cancer, 
but in medullary thyroid carcinoma, lack of bcl-2 expression is an independent 
predictor of worse prognosis (Viale et al. 1995). 
VEGF-C: angiogenesis
Vascular endothelial growth factor-C (VEGF-C) is a member of the VEGF 
family of polypeptide growth factors which play key roles in angiogenesis and 
lymphangiogenesis. VEGF-C, found in 1996 in human prostate cell lines 
(Joukov et al. 1996), binds vascular endothelial growth factor receptor –3 
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(VEGFR-3), which is speciﬁ cally expressed on lymphatic vessels and stimulates 
lymphangiogenesis (Alitalo and Carmeliet 2002, Stacker et al. 2002). VEGF-C 
shows high expression in cancers metastasizing to the lymph nodes (Jeltsch et 
al. 1997, Mandriota et al. 2001) including breast, lung, colorectal, pancreatic, 
prostate, oesophageal, and head and neck cancers (Kurebayashi et al. 1999, 
Tsurusaki et al. 1999, Niki et al. 2000, George et al. 2001, Kitadai et al. 2001, P 
et al. 2001, Skobe et al. 2001, Tang et al. 2001, Duff et al. 2003, Hanrahan et al. 
2003, Homer et al. 2003, Onogawa et al. 2004).
VEGF-C and the thyroid. Papillary thyroid cancer expresses VEGF-C (Bunone 
et al. 1999, Fellmer et al. 1999, Shushanov et al. 2000, Tanaka et al. 2002, 
Tanaka et al. 2002a, Hung et al. 2003). Some of these studies have demonstrated 
a correlation between lymph node metastasis and high VEGF-C (Bunone et al. 
1999, Tanaka et al. 2002a, Tanaka et al. 2002b), but no correlation exists with 
other clinical parameters. Tanaka et al. (2002b) studied expression of VEGF-
C immunohistochemically in 25 patients with recurrent PTC with distant 
metastases and in 50 with nonrecurrent PTC. VEGF-C correlated with lymph 
node involvement, but not with other clinical factors. Bunone et al. (1999) had 
a smaller number of PTC patients (68 thyroid tumours including 26 PTCs) and 
showed that of 26 PTC patients, 24 had lymph node metastases, and of those, 21 
expressed VEGF-C, as analyzed by RT-PCR and immunohistochemistry. Another 
RT-PCR analysis showed similar results: 48 of 50 PTCs expressed VEGF-C, and 
patients with nodal involvement showed higher expression of VEGF-C mRNA 
(Tanaka et al. 2002a). 
MMP-2: invasion and metastasis
Matrix metalloproteinases (MMPs) form a continuously growing family of zinc-
dependent endopeptidases that degrade extracellular matrix components and 
facilitate invasion (Egeblad and Werb 2002). MMPs are classiﬁ ed into subfamilies 
based on their substrate preferences. Until now, 21 members of the MMP gene 
family have been discovered (Vihinen and Kähäri 2002). MMP-2 (Gelatinase A, 
72 kDa type IV collagenase) is a metalloproteinase that speciﬁ cally cleaves type 
IV collagen, the major structural component of basement membrane (Liotta et al. 
1979). It is therefore closely associated with the malignant behaviour of tumour 
cells. MMP-2 expression is linked to invasiveness in several human neoplasms 
including breast, colon, ovarian, lung, prostate, kidney, bladder, hepatocellular 
carcinomas and melanoma (Sier et al. 1996, Young et al. 1996, Talvensaari-
Mattila et al. 1998, Kitamura et al. 1999, Ogata et al. 1999, Hofmann et al. 2000, 
Chan et al. 2001, Ross et al. 2003, Vasala et al. 2003). The MMP-2 has been 
localized immunohistochemically to tumour cells and to stromal cells (Grigioni 
et al. 1994). 
MMP-2 and thyroid. In 1992, Campo et al. demonstrated that malignant thyroid 
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tumours including PTC express MMP-2, and in PTC staining was diffuse 
and intracytoplasmic. More aggressive variants like the tall cell variant of PTC 
and invasive follicular carcinoma show stronger expression than do low-grade 
tumours (Campo et al. 1992). In 1996, results of Zedenius et al. supported 
these ﬁ ndings, however, the number of papillary carcinomas was low. They 
demonstrated that four of ﬁ ve PTC showed a strong hybridization signal and 
in all cases the signal for MMP-2 was seen in the stroma surrounding invading 
tumour cells. Later, Nakamura et al. (1999) demonstrated that among seven 
different MMPs, only MMP-2 production was higher than normal in PTC tissue. 
MMP-2 was immunolocalized in carcinoma cells and stromal ﬁ broblasts. Maeta 
et al. (2001) showed in a large number of cases (n=86 PTC) that expression of 
MMP-2 was associated with large tumour size, high stage, high intrathyroidal 
invasion, capsular invasion, high vascular invasion, and lymph node metastasis. 
Immunolocalization of MMP-2 was mainly to tumour cells and less frequently 
to stromal mesenchymal cells. 
COX-2: invasion and metastasis 
Cyclooxygenase-2 (COX-2) is the key enzyme in the conversion of arachidonic 
acid (AA) into prostanoids. Two COX isoforms have been cloned. COX-1 is 
produced constitutively, while COX-2 is induced rapidly in response to growth 
factors, hormones, cytokines, and tumour promoters. These inﬂ ammatory 
mediators are thought to play a critical role in the initiation and maintenance 
of cancer cell survival and growth. COX-2 is up-regulated in several malignant 
epithelial neoplasms and it plays an important role in carcinogenesis. Expression 
of COX-2 correlates with poor prognosis in colorectal (Sheehan et al. 1999), breast 
(Ristimäki et al. 2002), oesophageal (Buskens et al. 2002), cervical (Gaffney et 
al. 2001), and ovarian cancer (Denkert et al. 2002, Erkinheimo et al. 2004). 
In colon carcinogenesis, the COX-2 enzyme is the rate-limiting step. Selective 
COX-2 inhibitors have been shown to prevent intestinal tumour formation and 
inhibit colon carcinoma growth in animal models (Oshima et al. 1996, Sheng 
et al. 1997). COX-2 supports tumour growth by inhibiting apoptosis (Tsujii 
and DuBois 1995), stimulating angiogenesis (Tsujii et al. 1998, Masferrer et al. 
2000), and increasing tumour invasion and metastatic potential (Tsujii et al. 
1997, Kakiuchi et al. 2002, Niki et al. 2002). 
COX-2 and the thyroid. Recent results indicate that COX-2 expression is 
upregulated also in human thyroid carcinoma (Cornetta et al. 2002, Nose et 
al. 2002, Specht et al. 2002). Association of COX-2 and thyroid disease was 
ﬁ rst reported by Di Paola et al. in 1997. They demonstrated that indometacin, 
a cyclooxygenase inhibitor, inhibits thyroid cell proliferation in patients with 
Graves` disease. Based on their ﬁ ndings, they suggested that thyroid growth 
might depend on activation of the cyclooxygenase pathway. In 1999, Smith 
et al. examined COX-2 expression in thyroid cancer and found that normal, 
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autoimmune and neoplastic human thyroid epithelium express COX-2. In 
addition, they demonstrated COX-2 expression in the human thyrocyte cell line 
KAT-50. In contrast, Berg et al. (2000) reported that COX-2 gene expression is
inducible only upon stimulation with cytokines, and the normal thyroid does 
not express COX-2. The pro-inﬂ ammatory cytokines, interleukin-1β (IL-1β) and 
Tumour Necrosis Factor-α (TNF-α), raised COX-2 expression in a human thyroid 
cell line. Cornetta et al. (2002) supported these results, showing that COX-2 
is expressed in papillary and follicular thyroid tumours and in Hashimoto`s 
thyroiditis, but not in normal thyroid or in goiter. Interestingly, they also showed 
that anaplastic thyroid carcinomas do not express COX-2. They suggested that 
COX-2 may be involved in the progression of normal thyroid to differentiated 
carcinoma, whereas poorly differentiated tumours do not require COX-2 for 
growth. Recently, it was shown that follicular adenomas, papillary and follicular 
carcinomas and chronic lymphocytic thyroiditis over-express COX-2 (Nose et al. 
2002). Normal thyroid epithelium showed weak expression of COX-2. Specht 
et al. (2002) also demonstrated that COX-2 is up-regulated in human papillary 
thyroid cancer, but not in benign thyroid nodules; COX-2 mRNA was detected 
in ﬁ ne needle aspiration, and they suggested that COX-2 could serve as a marker 
of cancer. 
COX-2 inhibitors and cancer. Although COX-2 inhibitors were designed to relieve 
pain, several reports suggest that they may offer some protection against cancer, 
especially colon cancer. The ﬁ rst two trials were promising. After 6 months, the 
patients receiving 400 mg of celecoxib twice a day had a 28% reduction in the 
mean number of colorectal polyps as compared with a reduction of 4.5% in the 
placebo group (Steinbach et al. 2000). In another study, at 9 months, the polyp 
number in the rofecoxib group decreased by 6.8% from the baseline values, 
whereas that in the placebo group increased by 3.1%; polyp size was also reduced 
in the rofecoxib group as compared with the placebo group (Higuchi et al. 2003). 
These two studies reported no harmful side effects. Several clinical trials are now 
underway to determine whether COX-2 inhibitors have chemopreventive effects. 
Just recently, serious cardiovascular side effects were reported in two large trials 
(Bresalier et al. 2005, Solomon et al. 2005). Due to this, both rofecoxib and 
valdecoxib were removed from the market. It is not yet known whether these 
side effects seen with rofecoxib and valdecoxib are a general effect of COX-2 
inhibitors or a speciﬁ c effect of these two drugs. 
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Other markers
A number of other markers have been studied to conﬁ rm diagnosis and to predict 
prognosis of papillary thyroid carcinoma. Galectin-3 and mesothelioma antibody 
(HBME-1) have proven to be sensitive diagnostic markers for PTC (Weber et al. 
2004, Cvejic et al. 2005, de Matos et al. 2005). Promising prognostic tumour 
markers include cyclin D1, p27, retinoblastoma gene product (pRb), and E-
cadherin. Overexpression of cyclin D1 and underexpression of p27 have been 
shown to be predictors of lymph node metastases in PTC (Khoo et al. 2002, 
Lantsov et al. 2005). Ito et al. (2005) demonstrated that papillary microcarcinoma 
cases of clinically apparent metastases showed increased cyclin D1, pRb and Ki-
67, together with decreased p27. Lack of E-cadherin expression was demonstrated 
to be an adverse prognostic factor (von Wasielewski et al. 1997). Moreover, loss 
of E-cadherin immunostaining has been correlated with development of distant 
metastases and lymph node metastases (Scheumman et al. 1995, Naito et al. 
2001). 
review of the literature
34
6.
Aims of the Study
The purpose of this study was to ﬁ nd clinical or biological markers to predict the 
outcome of the individual PTC patient. 
The speciﬁ c aims of the present study were:
•To analyze all patients who underwent surgery for PTC at HUCH 
between 1957 and 1996
•To compare TNM, AMES, and MACIS staging systems in 
predicting the prognosis of PTC
•To ﬁ nd any possible association between increasing age and 
higher incidence of poor prognostic factors by comparing 
expression of COX-2, MMP-2, bcl-2, Ki-67, p21, and VEGF-C in 
young and older PTC patients
•To ﬁ nd markers to predict tumour behaviour by comparing the 
expression of COX-2, MMP-2, bcl-2, Ki-67, p21, and VEGF-C in 
non-aggressive and aggressive tumours
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7.
Patients and Methods
7.1 Patients
Study I
This series comprised 495 patients undergoing surgery for PTC at Helsinki 
University Central Hospital between 1967 and 1994. Medical records were 
studied retrospectively. All patients were followed up until the end of November 
1999. Any death certiﬁ cates were available from the Population Registry of 
Finland. 
Studies II, III, and V
To compare young and older patients, we analyzed 259 consecutive PTC-surgery 
patients at HUCH during a 10-year period (1987-1996). The cut-off age varies 
among scoring systems, but all cut-off ages are estimates. We selected all patients 
under age 35 for a young patient group and all patients over 55 for an older group 
(cut-off age of TNM classiﬁ cation +/- 10 years). The eventual total chosen with 
adequate clinical data was 108, and the tumour specimens of these patients were 
studied immunohistochemically. 
Study IV
This series comprised 601 consecutive patients who underwent surgery for PTC 
at HUCH between 1973 and 1996. Clinical data were collected retrospectively. 
Clinical outcome was checked at the end of December 2002, and survival data at 
the end of November 2003. Survival data and cause of death were obtained from 
the Population Registry of Finland. Mean follow-up was 14.5 years (range 5.0-29.3) 
for those last known to be alive, and 10.1 (range 0.1-28.0) for the deceased. 
From this initial series we selected 36 matched pairs for immunohistochemical 
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study to compare non-aggressive and aggressive tumours. All tumours were of the 
usual type. Each individual pair had similar clinical characteristics at diagnosis, 
but during follow-up their disease behaved differently, one patient recovered 
completely after primary surgery, and the other suffered from aggressive disease 
(aggressive disease vs completely-recovered pair). These pairs were matched by age 
(within 10 years), gender, timing of primary operation (within 10 years), T stage, 
N stage, tumour size, and primary RAI ablation (yes/no). Disease was deﬁ ned 
as aggressive if a need existed for more than three radioactive iodine ablations 
(with recurrences detected with scintigraphy), surgery for recurrent disease more 
than once within 6 months after the primary operation, development of distant 
metastases 6 months after the primary operation, primary distant metastases, or 
death from PTC. 
Non-published data
In addition we analyzed clinical data of patients who underwent surgery for PTC 
at HUCH between 1957 and 1972. We excluded these patients from Studies II 
to V, because the method of ﬁ xation of samples changed in 1973, and samples 
from the previous period were unsuitable for immunohistochemistry. The other 
reason for exclusion was that only after 1973 the standard treatment for PTC at 
HUCH was total thyroidectomy. 
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7.2 Methods
Immunohistochemistry (Studies II-V)
All tissue specimens were obtained from PTC operations performed at HUCH 
from 1973 to 1996. Formalin-ﬁ xed, parafﬁ n-embedded archival tissue blocks 
were freshly cut into 4- m sections onto slides and dried for 12 to 24 hours at 
37°C. Freshly cut sections were deparafﬁ nized in xylene and rehydrated through 
graded alcohol and deionized water. Then sections were heated in a microwave 
oven in 0.3% citrate buffer (pH 6.0) for 4 x 5 min, and washed with phosphate-
buffered saline (PBS) for 2 x 5 min. Endogenous peroxidase activity of the tissues 
was inactivated by 30 minutes incubation in methanol containing 1.6% hydrogen 
peroxide followed by PBS wash for 3 x 5 min. To block nonspeciﬁ c binding 
sites, the sections were then treated with normal horse serum for 15 minutes. 
The antibodies for COX-2, MMP-2, bcl-2, Ki-67, p21, and VEGF-C were used 
for overnight incubation (Table 3). After overnight incubation with the primary 
antibody, the sections were ﬁ rst reacted for 30 min with biotinylated anti-mouse 
IgG diluted in PBS containing 1% normal horse serum or anti-rabbit IgG 
diluted in PBS containing 1% normal goat serum, and then for 30 min in avidin-
biotinylated peroxidase complex (Vectastain ABC Kits, Vector Laboratories, Inc., 
Burlingame, CA, USA). Between each step in the staining procedure, sections 
were washed three times with PBS for 5 minutes. Staining was visualized with 3-
amino-9-ethyl-carbazole (A5754; Sigma, St. Louis, MO, USA), 0.2 mg/ml in 0.5 
M acetate buffer containing 0.03% hydrogen peroxide (pH 5.0) for 15 minutes. 
Finally, the sections were washed thoroughly in tap water, counterstained lightly 
with Meyer´s haematoxylin, washed, and mounted in aqueous mounting media 
(Aquamount; BDH, Poole, UK). 
Formalin-ﬁ xed, parafﬁ n-embedded specimens of colorectal cancer known to be 
positive for COX-2, MMP-2, Bcl-2, and p21 served as positive controls. Specimens 
of breast cancer served as positive controls for VEGF-C and Ki-67. As the negative 
control we used PBS instead of primary antibody.
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Scoring
The scoring of COX-2 was performed independently and in a blinded manner 
by two investigators (AR and PS), and when scores were discrepant, scoring was 
determined after discussion. Scoring of MMP-2, VEGF-C, Bcl-2, Ki-67, and p21 
was performed by pathologist (SN) and by an investigator (PS) blinded to the 
clinical data. 
COX-2. COX-2 immunoreactivity was assessed by intensity of staining and 
percentage of positive area. Intensity of the staining was scored 0 to 3 (absent; 
mild; moderate; strong), and the area of positivity was estimated as percentage 
of the total area of the tumour (under 10%, between 10 and 49%, and over 50%). 
The ﬁ nal score was a combination of these two variables as follows. Score 0: 
negative staining or intensity 1 under 10%; score 1: intensity 1 between 10 and 
100% or intensity 2 to 3 under 10%; score 2: intensity 2 over 10% or intensity 3 
under 50%; score 3: intensity 3 area over 50%. Positive expression of COX-2 was 
deﬁ ned as intensity 2 to 3 seen over 10% of the total area (scores 2-3). 
MMP-2, bcl-2, VEGF-C. Cytoplasmic immunoreactivity for MMP-2, bcl-2, and 
VEGF-C was evaluated according to extent of staining. Positive expression was 
deﬁ ned as more than 10% of the tumour area stained. Epithelial expression of 
Table 3 Antibodies, their dilutions and sources. 
Antibody Dilution Manufacturer Study
COX-2
Mouse anti-human 
monoclonal antibody
1:200
160112, Cayman Chemical, 
Ann Arbor, MI, USA
II, IV
MMP-2 
mouse monoclonal 
antibody antibody
1:700
Neomarkers, Fremont, CA, 
USA
II, IV
Bcl-2
mouse anti-human 
monoclonal antibody
1:400
Dako, clone 124, Glostrup, 
Denmark
III, IV
Ki-67
rabbit polyclonal 
antibody
1:500 Dako III, IV
P21
mouse monoclonal 
antibody
1:200
Novo Castra Laboratories, 
Newcastle-Upon-Tyne, UK
III, IV
VEGF-C
rabbit polyclonal 
antibody
1:500
Zymed Laboratories, Inc., 
South San Francisco, CA, USA IV, V
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MMP-2 (cancer cell) and stromal staining were evaluated separately. 
Ki-67, p21. Nuclear immunostaining for Ki-67 and p21 was estimated, and 
immunoreactivity was expressed as the percentage of positive tumour cell nuclei 
per tumour; p21 expression was graded as negative (≤ 5%) or positive (> 5% 
of tumour cells stained) and the cut-off value for Ki-67 expression was 1%. In 
the work of Räty et al. (2002), ﬁ ndings with a grid-counting and with simple 
estimation of percentage of stained cells (Ki-67) were similar. As expression of 
Ki-67 in differentiated thyroid tumours is low (Wallin et al. 1992, Katoh et al. 
1995, Basolo et al. 1997, Okayasu et al. 1998, Tallini et al. 1999, Yoshida et al. 
1999, Saiz et al. 2002), we deﬁ ned the cut-off value for positivity as 1%. 
Cell culture (Study V)
The cells were grown in RPMI reagent supplemented with 10% fetal calf 
serum (Promo Cell, Heidelberg, Germany), 2mM L-glutamine, and antibiotics 
(BioWhittager, Verviers, Belgium). Cells were incubated with phorbol 12-
myristate 13-acetate (PMA) (10 ng/ml; Sigma), NS-389 (5-10 M; Cayman), 
arachidonic acid (10 M; Sigma) for selected time periods.
PGE
2
 and VEGF-C EIA. Prostaglandin E2 (PGE
2
) levels were measured from cell 
culture medium by Enzyme Immuno Assay (EIA) from Cayman Chemical Co 
and VEGF-C production by EIA from Zymed (San Francisco, CA, USA) according 
to manufacturer´s instructions.
RT-PCR. Total RNA from NPA cells was isolated by use of Trizol Reagents 
(Invitrogen, Carlsbad, CA, USA) and RNA (1 g) was converted to cDNA with 
Moloney murine leukemia virus reverse transcriptase (Promega, Madison, 
WI, USA), RNasin (Promega), 2’deoxynucleoside 5’triphosphates (Amersham 
Pharmacia Biotech Inc, Buckinghamshire, England), and random primers 
(Invitrogen). COX-2 and VEGF-C mRNA expression was quantiﬁ ed by using 
TaqMan real-time RT-PCR and Gene Amp 5700 Sequence Detection System 
(Applied Biosystems, Foster City, CA). VEGF-C primers and TaqMan probe 
sequences were by Hung et al. (2003) and were purchased from Sigma Chemical 
Co. Human TATA-binding protein (TBP) served as an endogenous control to 
normalize the expression of VEGF-C and COX-2 mRNA levels. COX-2 and TBP 
Assays-on-Demand were purchased from Applied Biosystems. Each reaction was 
run in triplicate and relative quantitation was performed by the comparative CT 
method (Applied Biosystems User Bulletin #2).
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7.3 Statistical analysis
Statistical analysis was performed with SPSS software (SPSS Inc., Chicago, 
IL, USA). A p-value less than 0.05 was regarded as statistically signiﬁ cant. The 
following test were used: 
I Carcinoma-speciﬁ c survival curves for each classiﬁ cation systems were calculated 
by the product-limit method, and log-rank test values served in comparisons. The 
proportion of variance in the outcome explained by each staging classiﬁ cation 
was calculated by consideration of each classiﬁ cation separately as a linearly 
increasing prognostic factor in the Cox proportional hazards regression model. 
II, III, V The chi-square test (or Fisher´s exact test when applicable). 
IV The chi-square test (or Fisher´s exact test when applicable), the Kaplan-Meier 
method, and the log-rank test.
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8.
Results
The individual publications are referred to by their Roman numerals. For 
additional tables and ﬁ gures, see each individual article. 
8.1 Classiﬁ cation systems (Study I)
We compared AMES, MACIS, and TNM classiﬁ cations to study which 
classiﬁ cation is the most reliable in predicting PTC patient prognosis. 
According to these classiﬁ cation systems, the low-risk group included 85.8% of 
patients (n= 425) in the TNM classiﬁ cation, 89.7% (n= 444) in the AMES, and 
89.9% (n= 445) in the MACIS system. According to the TNM system, there 
were three carcinoma deaths among low-risk Stage I patients. According to the 
MACIS system, six patients with scores up to 5.99 (low-risk) died of thyroid 
carcinoma. In the AMES system, as many as 12 fatal cancers occurred in the 
low-risk group. 
The TNM classiﬁ cation showed the highest mortality ratio between low-risk and 
high-risk patients at 5, 10, and 15 years after diagnosis. It was superior to the 
other staging systems when compared by the chi-square value of the log rank 
test, both in four prognostic groups and in comparison of low-risk and high-risk 
patients. Cancer-speciﬁ c survival seemed to be most reliably predicted by the 
TNM classiﬁ cation. 
In this series of 495 PTC patients, the most signiﬁ cant predictors of survival were 
presence of distant metastases (p < 0.0001), of nodal metastases (p = 0.004), age 
(p = 0.0087), and diameter of the primary tumour (p = 0.0189) in patients over 
45 years old. In the subgroup of patients under 45, neither distant metastases, 
nor nodal metastases nor diameter of primary tumour were signiﬁ cant predictors 
of survival. 
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8.2 Outcome of 601 patients (Study IV)
Clinical characteristics of these 601 patients are shown in Table 4. Mean age was 
45 years, and female to male ratio 3.8. Of the 601 patients, 479 (80%) recovered 
completely after primary surgery and had no problems during follow-up. During 
follow-up, tumours recurred in a total of 91 (15%) patients; 33 patients (5%) 
experienced distant metastases; 23 patients (4%) died of PTC. 
In univariate survival analysis, age over 45, tumour size > 4 cm, extrathyroidal 
extension of tumour, nodal metastases, distant metastases, and stage IV disease 
signiﬁ cantly correlated with survival. Gender was not a signiﬁ cant prognostic 
factor. 
When comparing patients under and over 45 years, the latter had more 
extrathyroidal disease, distant metastases, and their tumours were more 
aggressive during follow-up because each patient (n = 23) who died of PTC was 
over 45 at diagnosis. Lymph node metastases seemed to be more frequent among 
the patients under 45. 
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Table 4 Clinical characteristics of 601 papillary thyroid cancer (PTC) patients, with 
Tumour-Node-Metastases (TNM) stage according to the International Union Against 
Cancer (UICC) TNM classiﬁ cation of 1997.
Patient
Characteristics
All patients
(n= 601)
<45 years
(n= 313)
>45 years
(n= 288)
Mean age (range) 45 (5-83)
Women 477 251 226
Men 124 62 62
Female/male ratio 3.8:1 4:1 3.6:1
n (%) n (%) n (%)
Tumour size (cm)
≤1 170 (28) 92 (29) 78 (27)
1-4 360 (60) 189 (60) 171 (60)
> 4 68 (12) 31 (10) 37 (13)
Extent of tumour
  T1 (≤ 10 mm) 165 (27) 91 (29) 74 (26)
  T2 (> 10 mm, ≤ 40 mm) 310 (52) 170 (54) 140 (49)
  T3 (> 40 mm) 48 (8) 29 (9) 19 (7)
  T4 (beyond the capsule) 75 (13) 22 (7) 53 (19)
Nodal metastases 118 (20) 70 (22) 47 (16)
Distant metastases 13 (2) 3 (1) 10 (3)
TNM Stage
I 381 (63) 311 (99) 70 (24)
II 136 (23) 2 (1) 134 (47)
III 75 (12) 75 (26)
IV 9 (2) 9 (3)
Neck recurrence 89 (15) 50 (16) 39 (14)
Distant recurrence 20 (3) 1 (0.3) 19 (7)
Recurrence 91 (15) 50 (16) 41 (14)
Death from PTC 23 (4) 0 23 (8)
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Fatal cases (Tables 5-6). Of 601 patients, 23 died of PTC (4%). All of them were 
over 45. Mean age at initial treatment was 67.3 years and mean survival time 
from initial treatment to death 79 months. Total thyroidectomy was performed 
for 20 patients (87%) and primary RAI ablation was given for 17 patients (74%). 
Macroscopically curative surgery was carried out for 15 patients (65%). Primary 
distant metastases were present in 8 (35%), 3 of whom developed more distant 
metastases at other sites, and 13 new patients developed distant metastases 
during follow-up (56%). Histologically, of the 23, 22 tumours were of the usual 
type, and one was tall cell variant. In addition, one patient was diagnosed with 
anaplastic carcinoma at the time of death. Lungs were the commonest site of 
distant metastases; at the time of death, 16 patients (70%) had metastases in 
the lungs. Respiratory problems were the most common cause of death: widely 
spread multiple pulmonary metastases were responsible for death in 11 patients 
and airway obstruction due to local disease in 3. Extensive bone metastases were 
responsible for death in 4 patients and one developed liver coma due to liver 
metastases. The last 4 were in poor general health as a consequence of multi-
organ metastases and speciﬁ c cause of death could not be determined.
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Table 5 Details of 23 patients dying of papillary thyroid cancer. 
Patient
Characteristics n (%)
n of death 23/ 601 (4%)
Mean age at presentation, 
yrs (range)
67.3 (49-81)
Female/male ratio 2.3:1
Mean survival time, 
months (range) 79 (3-218)
Extent of tumour
  T1 (≤ 10 mm) 1 (4)
  T2 (> 10 mm, ≤ 40 mm) 6 (26)
  T3 (> 40 mm) 4 (17)
  T4 (beyond the capsule) 12 (52)
Mean size, cm (range) 4,3 (1-10)
Nodal metastases 12 (52)
Distant metastases 8 (35)
Secondary distant metastases 13 (57)
Neck recurrence 16 (70)
Table 6 Site of primary and secondary distant metastasis in papillary thyroid cancer 
patients with fatal disease (n=23). 
Site
Primary
(n= 8)
Secondary
(n= 13)
Total n (%)
Lung 5 10 15 (65)
Bone 3 5 8 (35)
Mediastinum 1 1 2 (9)
Liver 2 1 3 (13)
Kidney 1 0 1 (4)
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8.3 Non-published data
We analyzed clinical data from patients who underwent surgery at HUCH from 
1957 to 1972. These patients were excluded from immunohistochemical studies 
because the histological samples of the archives had been ﬁ xed in non-buffered 
formalin and the specimens were not reliable for immunohistochemical detection 
of antigens. In addition, treatment for PTC has changed over the years; since 
1973 total thyroidectomy has been the standard method. Death from PTC has 
declined (Table 7). 
Table 7 Death from papillary thyroid cancer (PTC) and treatment strategies between 1957 
and 1996 at Helsinki University Central Hospital. 
O p e r a t i o n s , 
years
Number 
of 
patients
Deaths 
from 
PTC
(%)
Total 
thyroid-
ectomies
(%)
Radioactive 
iodine
ablations
(%)
1957-1969 50 16 (32) 7 (14) 41 (82)
1970-1979 167 12 (7) 123 (74) 59 (35)
1980-1989 227 6 (2.6) 205 (90) 143 (63)
1990-1996 238 5 (2.1) 217 (91) 206 (87)
results
47
8.4 Immunohistochemistry (Studies II-V)
Of our two patient groups in immunohistochemistry, one included 108 patients 
selected by age (under 35 and over 55 years), and the other 36 matched pairs 
selected by behaviour of tumour (aggressive vs. completely recovered). Clinical 
characteristics of these four groups are shown in Table 8.
Table 8 Clinical characteristics of papillary thyroid cancer patients in four 
immunohistochemical groups. Tumour-Node-Metastases (TNM) stage according to 
International Union Against Cancer (UICC) TNM classiﬁ cation of 1997.
Patient
Characteristics 
at presentation
Under 35
n (%)
Over 55
n (%)
36 matched pairs 
n (%)
Aggressive 
disease
Completely 
recovered
Study II, III, V IV
n patients 59 49 36 36
Mean age 27.8 64 47.7 46.2
Women 48 38 25 27
Men 11 11 11 9
Female/male ratio 4.3:1 3.5:1 2.3:1 3:1
Extent of tumour*
T1 (≤ 10 mm) 11 (19) 14 (29) 4 (11) 4 (11)
T2 (> 10 mm, ≤ 40 mm) 37 (63) 24 (49) 18 (50) 18 (50)
T3 (> 40 mm) 6 (10) 1 (2) 7 (19.5) 7 (19.5)
T4 (beyond the capsule) 5 (8) 10 (20) 7 (19.5) 7 (19.5)
Nodal metastases 20 (34) 7 (14) 12 (33) 12 (33)
Distant metastases 0 0 6 0
TNM Stage
I 59 (100) 14 (29) 17 (47) 18 (50)
II 0 22 (45) 8 (22) 9 (25)
III 0 13 (26) 7 (20) 9 (25)
IV 0 0 4 (11) 0
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Studies II, III, V
Expression of tumour markers was studied in PTC in two age groups: under 35 
and over 55 (Table 9 and Figure 2). 
Table 9 Number of patients with positive expression of COX-2, MMP-2, bcl-2, ki-67, p21, 
and VEGF-C in papillary thyroid cancer in patients under 35 and over 55 at diagnosis. 
All patients
n (%)
Under 35
n (%)
Over 55
n (%)
p-value
young vs old
COX-2 38 (35) 13 (22) 25 (51) 0.002
Epithelial MMP-2 20 (19) 9 (15) 11 (22) NS
Stromal MMP-2 37 (34) 19 (32) 18 (36) NS
bcl-2 28 (26) 16 (27) 12 (24) NS
Ki-67 32 (30) 12 (20) 20 (42) 0.017
p21 78 (72) 42 (71) 36 (74) NS
VEGF-C 40 (38) 12 (21) 28 (57) < 0.001
Figure 2. Number of patients with positive expression of COX-2, MMP-2, bcl-2, ki-67, p21, 
and VEGF-C in papillary thyroid cancer in patients under 35 and over 55 at diagnosis 
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COX-2. COX-2 expression was higher in older patients (p= 0.002) and correlated 
with high stage (p= 0.031), but not with other clinical parameters. 
The staining pattern of COX-2 in tumour cells was cytoplasmic. Nonneoplastic 
thyroid epithelium adjacent to carcinoma was negative or only weakly positive. 
Most positive tumours were only moderately positive (33 of 38). In ﬁ ve patients, 
COX-2 expression was strong. All these patients had tumour sized 1 cm to 4 cm, 
and no lymph node or distant metastases. They were aged between 21 and 79, 
and had no recurrences during follow-up. 
MMP-2. Stromal expression of MMP-2 correlated with the extent of primary 
tumour (p= 0.038), and in older patients with stage (p= 0.039). 
Expression was higher in tumours sized 1 to 4cm and in extrathyroidal tumours 
and at stages II and III. This series included no stage IV tumours. Epithelial 
expression of MMP-2 did not correlate with clinical parameters. 
MMP-2 was immunolocalized both to the cancer cells and stromal cells. Stromal 
staining was stronger: 37% of tumours expressed stromal MMP-2, but only 20% 
showed epithelial expression. 
Bcl-2. Expression of Bcl-2 correlated neither with clinical parameters nor with 
recurrent disease. 
The staining pattern was cytoplasmic. Of 28 positive cases, 19 were moderately 
positive and 9 strongly.
Ki-67. Ki-67 expression was higher in older patients (p=0.017) and correlated 
with stage (p=0.013), but not with other clinical parameters.
In the 32 Ki-67 -positive tumours, positive nuclear immunostaining was usually 
low (<10%), except in one tumour, which showed over 50% expression. This 
patient was a 30-year-old woman with a T2N0M0 stage tumour, and she had had 
no recurrences during follow-up. 
Tumour-associated lymphocytes seemed to be positive for Ki-67. However, we 
did not collect data systematically from these observations.
p21. Expression of p21 was associated with large tumours (p= 0.010) and with 
tumours extending beyond the thyroid capsule (p= 0.007). 
Positive nuclear immunostaining of p21 (>5%) occurred in as many as 78 of 108 
(72%) tumours. The percentage of p21-positive cells ranged from 0% to 60%, 
with a median value of 14%. 
VEGF-C. Expression of VEGF-C was higher in older patients (p < 0.001) and in 
older patients with lymph node metastases (p = 0.001). 
Staining pattern was cytoplasmic. Lymph node metastases were present in 26 
patients, with VEGF-C expression positive in 8. Among these lymph node-positive 
patients, VEGF-C immunoreactivity appeared in only 2 of 19 younger and in 6 
of 7 older patients. Thus, most older node-positive patients were also VEGF-C-
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positive, and conversely, most young patients with lymph node metastases did 
not express VEGF-C. 
Of the 106, we classiﬁ ed 5 patients as at high-risk. These patients either died 
of cancer or developed distant metastases during follow-up. All these high-risk 
patients were older, and 4 of them expressed VEGF-C. 
Associations between markers
COX-2 expression correlated strongly with VEGF-C expression (p < 0.001), and 
low expression of COX-2 correlated with low epithelial expression of MMP-2 
(p=0.047). Stromal expression of MMP-2 did not correlate with expression of 
COX-2.
Expression of bcl-2 was associated with expression of p21 (p=0.019) with no 
strong correlation, as most tumours were bcl-2-negative (80 of 108, 74%) and 
p21-positive (78 of 108, 72%). Positive expression of Bcl-2 was associated with 
positive expression of p21 and conversely, negative expression of p21 correlated 
with negative expression of bcl-2. 
Study IV
In Study IV, we had 36 matched pairs (aggressive disease versus completely 
recovered). No marker showed any signiﬁ cant difference between groups. 
Of 72 tumours, 31% expressed COX-2 (aggressive 31%; completely recovered 
28%), 4% epithelial MMP-2 (6%; 3%), and 21% expressed stromal MMP-2 (19%; 
22%), 28% expressed VEGF-C (31%; 25%), 35% Bcl-2 (39%; 31%), 14% expressed 
Ki67 (11%; 17%), and 42% p21 (36%,;47%). Expression of VEGF-C and bcl-2 
was slightly higher in the aggressive group. In contrast, Ki-67 and p21 showed 
slightly higher expression in the completely recovered group. 
Expression of COX-2 and VEGF-C seemed to be higher in older patients, 
conﬁ rming the results of Studies II and V. COX-2 was expressed in 15 of 19 
patients over 45, but in only 7 of 17 patients under 45. Numbers for VEGF-C 
were, correspondingly, 13 of 19 and 7 of 17. 
Histology (Studies II-V)
In our series of 108, were three PTC variants, two diffuse sclerosing variants, and 
one oncocytic variant (Hürthle cell PTC). In our series of 72 patients, all tumours 
were of the usual type. 
All three histologic variants were women under 35 and they were staged 
T2N0M0, T3N1M0, and T1N0M0. Two of them were cured by surgery, and one 
suffered from local recurrences (diffuse sclerosing variant T3N1M0). Expression 
of tumour markers in these patients is shown in Table 10. 
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Table 10 Expression of COX-2, MMP-2, Bcl-2, Ki-67, p21, and VEGF-C in two diffuse 
sclerosing variant and in one oncocytic variant. 0 = negative, + = positive expression.
Histologic 
variants
COX-2
MMP-2
epithelial
MMP-2
Stromal
Bcl-2 Ki-67 P21 VEGF-C
Diffuse 
sclerosing 
+ 0 + 0 + + 0
Diﬀ use 
sclerosing
+ 0 0 0 + + 0
Oncocytic 
variant
0 + + 0 + + 0
Fatal cases (Studies II-V)
Combined data from the immunohistochemical series of 108 patients and of 72 
patients included 13 fatal cases (Table 11). Half of the fatal cases expressed COX-2 
and VEGF-C; expression of other markers was lower. 
Table 11 Expression of COX-2, MMP-2, Bcl-2, Ki-67, p21, and VEGF-C in 13 fatal cases. 0 
= negative, + = positive expression. 
COX-2
MMP-2
epithelial
MMP-2
stromal
Bcl-2 Ki-67 P21 VEGF-C
1 0 0 0 0 0 0 0
2 + 0 0 0 + 0 0
3 + 0 0 0 0 0 0
4 0 0 0 + 0 0 +
5 + 0 0 + 0 0 +
6 + 0 0 0 0 0 0
7 0 0 0 0 0 0 0
8 0 0 0 + 0 0 0
9 + 0 0 0 0 0 +
10 + 0 0 + 0 + +
11 0 0 + + 0 + 0
12 0 0 0 0 + + +
13 + 0 + 0 + 0 +
Total
 n (%)
7 (54) 0 2 (15) 5 (38) 3 (23) 3 (23) 6 (46)
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Figure 3. A-B. Immuhohistochemical staining of COX-2 in papillary thyroid carcinoma. 
C. Senior and junior surgeon performing thyroidectomy for patient with papillary thyroid 
cancer. D. 3-cm tumour in the left thyroid lobe. 
8.5 Cell culture (Study V)
We showed that NPA cells expressed VEGF-C and COX-2 mRNA and that their 
expression was induced by PMA. At the protein level, after AA incubation, PMA 
induced PGE
2
 production, and the COX-2 selective inhibitor NS-398 blocked 
both basal and PMA-induced PGE
2
 synthesis. Moreover, PMA raised VEGF-C 
protein production after 24 h incubation by 2.7-fold, but NS-398 reduced neither 
basal nor PMA-induced VEGF-C expression. 
B. 
D. 
A.
C.
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9.
Discussion
9.1 Classiﬁ cation systems 
In our series of 495 patients, the TNM classiﬁ cation was the most reliable for 
predicting outcome of individual patients. Thus, we agree with another study 
that showed no statistically signiﬁ cant superiority of any system over the TNM 
classiﬁ cation (Brierley et al. 1997). TNM classiﬁ cation is the only classiﬁ cation 
system that does not ignore the effect of lymph node metastases on survival, and 
we assume that perhaps this fact made it superior to others. In the subgroup 
of patients over 45 years old, the most signiﬁ cant predictors of survival were 
presence of distant metastases, nodal metastases, age, and diameter of the 
primary tumour, whereas in patients under 45, those factors were not signiﬁ cant 
predictors. Similarly, the TNM system classiﬁ es all patients under 45 into the low-
risk category (Stage I-II), despite lymph node metastases or distant metastases. In 
patients over 45, however, the TNM classiﬁ cation takes lymph node metastases 
into account in predicting prognosis. 
According to the MACIS system, six of our patients who died of thyroid carcinoma 
were in the low-risk group. Of these six, ﬁ ve were over 45 and ﬁ ve had cervical 
node metastases. Based on the AMES system, 12 fatal cancers occurred in the low-
risk group, and also, the majority (83%) of these patients were older (over 45) and 
had nodal metastases (67%). Thus, old age together with lymph node metastases 
seems to have an adverse effect on survival, and the TNM classiﬁ cation focus on 
those points. 
Improving knowledge as to the effect on prognosis of primary tumour size and 
local invasion has justiﬁ ed some changes in TNM classiﬁ cation. In the new TNM 
classiﬁ cation (Sobin and Wittekind 2002), tumours under 2 cm belong to T1; 
in contrast, in the earlier TNM classiﬁ cation (Sobin and Wittekind 1997), only 
tumours under 1 cm belonged to T1. The new classiﬁ cation also includes tumours 
with minimal invasion in T3, in contrast to the 1997 TNM classiﬁ cation, in which 
all tumours extending beyond the thyroid capsule belonged in the T4 group. 
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9.2 Outcome of 601 patients
We analyzed a large series of PTC patients. Although their overall prognosis is 
good, a small group of PTC patients suffer from numerous recurrences or distant 
metastasis; some even die. The most important factor that affects prognosis is old 
age. In our study, all (n=23) patients who died of cancer were over 45, showing 
that young age alone was enough to protect them. 
Recurrent disease, however, occurs in young patients. Therefore, although PTC 
is among the most curable cancer types, it can be a distressing disease for those 
young patients suffering from frequent recurrences of lymph nodes. Patient’s 
awareness of the remaining cancer and the constant anguish of yet another 
recurrence can be very depressing. Also, from the aesthetic point of view, scars in 
the neck region from repeated operations on lymph node metastases contribute 
to lack of conﬁ dence. In our study, 50 of the 89 (56%) patients who suffered 
from local recurrences were under 45. 
Table 12 compares clinical characteristics of our series of 601 PTC patients to 
those of series in previous studies. In our series, the mean age 45 at diagnosis is 
quite similar to that reported by most others, but different from that of Mazzaferri 
et al. (1994) who reported a lower mean age. In that series, patients were under 
the care of the US Air Force and Ohio State University hospital; thus most of 
them were ﬁ t for work. 
The predominance of PTC in females was higher in our series than in others. 
As males may represent a more aggressive course of disease, our lower rate of 
distant metastases compared to those of some others (Carcangiu et al. 1985, 
Samaan et al. 1992, Gilliland et al. 1997) may relate to our sex ratio of 3.8:1.
As for nodal metastases, present in 15 to 66% in other studies, the incidence was 
low: 20%. The incidence of lymph node involvement depends not only on extent 
of surgery but also on the diligence of the pathologist, as microscopic involvement 
has been shown to be as high as 80 to 90% (Noguchi et al. 1998). Gross nodal 
metastases are present in approximately 30 to 40% of patients (Gilliland et al. 
1997, Noguchi et al. 1998). 
Our death rate of 4% is the average ﬁ gure, Mazzaferri et al. (1994) and Samaan 
et al. (1992) had higher death rates, 8% and 9%. Patients in those series were 
collected from 1950 to 1989, whereas other series included patients also from the 
1990s, except Hay et al. (1945-1985). Death rates declined in the 1990s, probably 
as a consequence of increased use of total thyroidectomy and RAI ablation. 
The incidence of tumour recurrence in our study was the lowest (15%). The 
recurrence rates in other series were between 20 and 33%. Sutton et al. (1988) 
suggested that differences in recurrence rates may relate to increased use of 
radionuclide neck scans and neck imaging with high-resolution ultrasonography. 
The differences in recurrence rate may also be due to differences in surgical 
strategy and postoperative treatment strategy. 
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Author n
Mean 
age
(years)
Women:
men
ratio
Nodal 
metas-
tases 
(%)
Distant 
metas-
tases
(%)
Distant 
recur-
rences
(%)
Any 
recur-
rence
(%)
Death
(%)
Carcangiu 241 41.3 2.6:1 54 6.5 11.5 5.8
Hay 1500 44 2:1 38 2 4 20 5.5
Mazzaferri 1077 35.7 2.2:1 46 2 5 21 8
Samaan 1289 40.6 2.3:1 38 5 6 23 9
Simon 176 43.6 2:1 66 3 7 33 3.9
Tzavara 677 44 3.2:1 15 2 6 21 2
Gilliland 11857 39 3.1:1 35 3.7 2
Range 35-44 2.1-3.1:1 15-66 2-6.5 4-11.5 20-33 2-9
Siironen 601 45 3.8:1 20 2 3 15 4
Based on our results for the outcome of 601 patients, we agree that age, extent 
of primary tumour, tumour size, and distant metastases are useful predictors 
of poor prognosis (Cady and Rossi 1988, Hay et al. 1993). Contradicting many 
others’ ﬁ ndings, in our series, nodal metastases had an unfavourable effect on 
survival. 
The prognostic signiﬁ cance of lymph node status is controversial. It is believed 
that papillary thyroid cancer is the only human cancer with no relationship 
between lymph node metastases and survival (Bacourt et al. 1986, DeGroot et al. 
1990, Samaan et al. 1992). Consistent with our results, however, some authors 
have found that LNM has a signiﬁ cant adverse effect on survival (Harwood et al. 
1978, Sellers et al. 1992, Scheumann et al. 1994). In our series, LNM incidence 
was almost the same in patients under and over 45 years, and lower than in 
most other series for younger patients. In our series, as the incidence of LMN 
was low for younger patients, the strong positive inﬂ uence of young age had no 
favourable effect on survival in patients with nodal metastases. The other reason 
could be the differing follow-up times. Our mean follow-up was 14.5 years for 
those last known to be alive, and 10.1 years for those who had died. The mean 
follow-up time in those studies showing a prognostic signiﬁ cance for LNM is 
usually over 15 years (Harwood et al. 1978, Tubiana et al. 1985, Sellers et al. 
1992, Shaha et al. 1994), whereas the average follow-up time in studies showing 
no inﬂ uence is often under 10 to 15 years (Bacourt et al. 1986, DeGroot et al. 
1990, Samaan et al. 1992, Akslen 1993, Hay et al. 1993). Relapses can occur as 
late as 30 years after primary treatment, and overall survival at 10 years therefore 
seems insufﬁ cient (Tubiana et al. 1985). Thus, the clinical signiﬁ cance of lymph 
Table 12 Clinical characteristics of our series of 601 PTC patients and other series 
(Carcangiu et al. 1985, Hay 1990, Samaan et al. 1992, Mazzaferri and Jhiang 1994, 
Simon et al. 1996, Gilliland et al. 1997, Tzavara et al. 1999). 
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node metastases in PTC might not be obvious after short-term follow-up. It is 
also notable that in our series, only gross nodal metastases were noted. Since we 
do not routinely perform lymph node dissection but only remove pathological 
lymph nodes, small lymph node metastases may have gone unnoticed. Thus, our 
positive lymph nodes probably represent only the most aggressive metastases, 
those which may inﬂ uence survival in contrast to micrometastases. 
Our ﬁ ndings support the fact that older PTC patients represent a biologically 
distinct group (Cady 1998). Many authors have reported that older PTC patients 
have more pathological risk factors (Tubiana et al. 1985, Bacourt et al. 1986, 
Samaan et al. 1992, Andersen et al. 1995, Coburn and Wanebo 1995, Kurozumi 
et al. 1998). In our series of 601 patients, extrathyroidal invasion of tumour, 
distant metastases, and aggressive disease were more common among those over 
45. Moreover, all patients who died of cancer were over 45. Similarly, others have 
shown that extrathyroidal invasion is related to older age (Samaan et al. 1992, 
Coburn and Wanebo 1995, Kurozumi et al. 1998). Also, authors have reported 
that distant metastases occur more frequently in those older (Bacourt et al. 1986, 
Samaan et al. 1992). Andersen et al. (1995) found that among the patients over 
45 incomplete resection did not signiﬁ cantly affect survival, and suggested that it 
was due to the more aggressive course of disease in older patients. 
In our study, male gender did not affect survival, but was associated with 
aggressive disease. Many studies agree that male gender has no inﬂ uence on 
survival (Hay et al. 1987, Simpson et al. 1987, Hay et al. 1993). Others have, 
however, demonstrated an independent inﬂ uence of gender on probability of 
relapse and survival (Byar et al. 1979, Tubiana et al. 1985, Akslen 1993). We 
believe that PTC in males is a more aggressive disease, at least their tumours 
seem to recur more easily than those of women. 
9.3 Tumour markers 
(immunohistochemistry and cell culture)
Our study included two patient series for immunohistochemistry: 108 patients 
aged under 35 and over 55, and 36 matched pairs. In matched-pair patients, the 
overall expression of all markers seemed lower. This difference may be attributable 
to the differing age and TNM stage distribution in these two groups. 
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COX-2, Ki-67 and VEGF-C
Higher expression in older patients. COX-2, Ki-67, and VEGF-C expression was 
higher in older PTC patients. Others have demonstrated a similar tendency for 
Ki-67 (Yoshida et al. 1999), but not for COX-2 or VEGF-C. In contrast to our 
results, COX-2 expression has been higher in younger patients in the study of 
Ito et al. (2003), which divided patients into those under and over 54 years old. 
Contradictory results may depend on the different cut-off limits for age and the 
fact that our study comprised a larger number of PTC specimens. In addition, 
we found that among lymph node-positive patients, VEGF-C expression was 
positive in most older patients, but only a few young ones expressed VEGF-C. 
Moreover, more than half the older lymph node-positive patients either died 
of cancer or developed distant metastases. To our knowledge, only two works 
have shown VEGF-C expression in thyroid tumours to be higher in patients with 
nodal involvement (Bunone et al. 1999, Tanaka et al. 2002a). In other studies, 
correlations of LNM with VEGF-C have appeared (Shushanov et al. 2000, Hung 
et al. 2003). To the best of our knowledge, relations between old age, LNM and 
VEGF-C expression have not been studied. 
Increased expression of COX-2 in our study may reﬂ ect the more aggressive 
behaviour of the tumours of older PTC patients, because COX-2 inhibits apoptosis 
(Tsujii and DuBois 1995), stimulates angiogenesis (Tsujii et al. 1998, Masferrer 
et al. 2000), and increases tumour invasion and metastatic potential (Tsujii et al. 
1997, Kakiuchi et al. 2002, Niki et al. 2002). Moreover, increased expression of 
Ki-67 means increased proliferative activity and thus faster-growing, aggressive 
tumours. However, Ki-67 recognizes proliferating cells and tells whether a cell 
is in the cycle, but it provides no information as to the length of the cell cycle. 
Thus, we cannot draw very strong conclusions about tumour behaviour based 
only on Ki-67 expression status (Brown and Gatter 1990). Increased VEGF-C 
expression has been shown to promote distant metastasis in breast cancer (Skobe 
et al. 2001). We think that up-regulation of VEGF-C in older lymph node-positive 
patients can lead to increased distant dissemination of tumour cells. Possibly 
due to VEGF-C, most older lymph node-positive patients either developed distant 
metastases or died of cancer. This supports other reports that nodal metastases 
indicate poor prognosis in older PTC patients (Harwood et al. 1978, Tubiana et 
al. 1985, Mazzaferri and Jhiang 1994, Passler et al. 2004). Our sample size was, 
however, small and inadequate for drawing ﬁ nal conclusions. We noticed a trend 
that VEGF-C could associate with distant dissemination of tumour cells in older 
patients. 
Lymph node dissection for older patients? Based on our ﬁ ndings that lymph 
node metastases impacted survival, and that all patients who died of PTC were 
older, and that immunohistochemical expression of VEGF-C was higher in those 
older, we agree that older PTC patients may beneﬁ t from prophylactic lymph 
node dissection (Passler et al. 2004). 
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At present, in our department as in most other Nordic hospitals, only palpable 
lymph nodes or lymph nodes suspected to be metastatic at ultrasound are removed 
(Mazzaferri and Young 1981). This recommendation is due to an agreement that 
lymph node metastases have no inﬂ uence on survival (McConahey et al. 1986, 
Shah et al. 1992) and thus the neck dissection may not be necessary. However, 
the literature is controversial regarding the impact of lymph node metastases. In 
the United States, the latest NCCN recommendation is to perform central and 
lateral neck dissection for PTC patients with lymph node metastases (Sherman 
et al. 2005). Our ﬁ ndings support that recommendation in cases of older lymph 
node-positive PTC patients. 
COX-2 inhibitors for older patients? As we found that COX-2 expression is higher 
in older patients and older PTC patients have a worse prognosis, inhibiting 
COX-2 by selective COX-2 inhibitors may improve the prognosis in older PTC 
patients. In fact, promising ﬁ ndings in colon carcinogenesis have shown that 
COX-2 inhibitors may offer some protection against colon cancer (Steinbach et 
al. 2000, Higuchi et al. 2003). However, further studies were affected when life-
threatening cardiovascular side effects were reported in two trials (Bresalier et al. 
2005, Solomon et al. 2005). It is not known whether these side effects were dose 
dependent or related to rofecoxib and valdecoxib. 
No correlation with patient outcome. In our series of matched pairs (aggressive 
versus completely recovered), COX-2, Ki-67, and VEGF-C expression did not 
correlate with aggressive disease. Among the 13 fatal cases from the two series, 
COX-2 expression was positive in 7, Ki-67 in 3, and VEGF-C in 6 tumours. Thus, 
our data do not conﬁ rm those of Sugitani et al. (1998) who found that in a small 
group of PTC microcarcinoma patients, Ki-67 expression is higher in those with 
lymph node metastases and with noncapsulated tumours, and moreover, patients 
who die of cancer show the highest Ki-67 expression. Expression of COX-2 and 
VEGF-C in our fatal cases was not higher than the expression of these markers 
in other older patients (Study II and V). One explanation for this could be that 
increased expression of these markers in older patients is only a reﬂ ection of a 
type of cancer biologically different from that in young patients. Cancer cells in 
older patients are more aggressive and invade distant organs and cause death. 
In young PTC patients, cancer remains in most cases in the neck region. In our 
series of 601 patients, no patients under 45 at initial diagnosis died of PTC. 
Correlation of COX-2 and VEGF-C. In our immunohistochemical study, 
expression of COX-2 and VEGF-C correlated strongly. In cell culture studies, 
NPA cells expressed both COX-2 and VEGF-C, but COX-2 selective inhibitor NS-
398 did not reduce VEGF-C expression, indicating that VEGF-C expression was 
not dependent on COX-2-derived prostanoids.
To the best of our knowledge, only three works in the literature have shown a 
correlation between COX-2 and VEGF-C (Byeon et al. 2004, Kyzas et al. 2004, 
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Su et al. 2004). In thyroid carcinoma, no correlation between COX-2 and VEGF-
C has been reported. 
A novel correlation between COX-2 and VEGF-C occurs in human lung 
adenocarcinoma (Su et al. 2004); in this work, they studied human lung 
adenocarcinoma cell lines and 59 patients who underwent surgery for lung 
adenocarcinoma. Immunohistochemical analysis of 59 lung adenocarcinoma 
specimens revealed that VEGF-C expression was signiﬁ cantly associated with 
the expression of COX-2 supporting our results in immunohistochemistry. They 
also showed that “high VEGF-C and COX-2 expression patients” were more likely 
to have lymph node metastasis and a shorter survival rate. Moreover, in contrast 
to our cell culture studies, Su et al. (2004) showed that in lung adenocarcinoma 
cell lines, COX-2 and its derived prostanoids are able to up-regulate the VEGF-C 
gene through the EP1 and HER-2/Neu-dependent pathway. A difference in tissue 
distribution of the prostanoid receptors may be one reason for these contradictory 
ﬁ ndings. However, we think that the same factors may control the expression of 
these two markers in PTC via a PGE
2
-independent pathways, as both COX-2 and 
VEGF-C were induced by PMA. 
In addition, a correlation between COX-2 and VEGF-C was shown in two 
immunohistochemical studies (Byeon et al. 2004, Kyzas et al. 2004). In a study 
of head and neck carcinoma (n= 70), increased expression of both markers also 
correlated with the presence of lymph node metastases and advanced clinical 
stage (Kyzas et al. 2004). In another work, as well, expression of VEGF-C in 
oesophageal squamous cell carcinoma was higher in lymph node-positive patients 
(Byeon et al. 2004). Of their 31 oesophageal squamous cell carcinoma patients, 
21 had lymph node metastases, and all of them expressed VEGF-C (Byeon et al. 
2004). 
P21
Views differ regarding the importance of p21 in PTC. In our study of 108 patients, 
p21 expression was higher in large tumours and in tumours inﬁ ltrating through 
the thyroid capsule. Therefore, we hypothesized that p21 may be a sign of a more 
aggressive tumour. In our matched-pair group of 72 patients, expression did not, 
however, correlate with aggressive disease. In addition, of 13 fatal cases, only 3 
expressed p21. These ﬁ ndings argue against Basolo et al. (1994) who showed that 
p21 correlates with tumour aggressiveness in PTC, because its expression was 
signiﬁ cantly higher in fatal cases. This inconsistency may be explained by too 
small patient series: In Basolo et al. (n=45) the number of fatal cases was only 14, 
in our series 13. In another study, the authors suggested that over-expression of 
p21 in thyroid tumours has a relationship to thyroid tumorigenesis, particularly 
in late events (Okayasu et al. 1998). In that study, anaplastic thyroid carcinomas 
and poorly differentiated papillary carcinomas showed higher immunostaining 
than did well-differentiated PTCs. As thyroid cancer is a slow-growing tumour, 
our ﬁ nding of higher p21 in large tumours and in extrathyroidal tumours supports 
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the role of p21 in late events in thyroid tumours (Okayasu et al. 1998). In contrast 
to reports showing the importance of p21 in thyroid tumours (Basolo et al. 1994, 
Akslen and Varhaug 1995, Okayasu et al. 1998), many researchers agree that p21 
expression has no clinical signiﬁ cance in thyroid cancer (Johnson et al. 1987, 
Mizukami et al. 1995, Ito et al. 1996). Based on our results, we could not suggest 
p21 as a prognostic marker in PTC, but it may take part in tumour progression. 
Bcl-2
In thyroid cancer, Bcl-2 expression associates with less aggressive histology 
(Pilotti et al. 1994, Pollina et al. 1996, Basolo et al. 1997, Moore et al. 1998). High 
bcl-2 reﬂ ects a slow growth pattern, thus favouring a good prognosis. Lack of bcl-
2 expression has been a sign of aggressive disease in medullary thyroid cancer, 
(Viale et al. 1995), but not in other thyroid cancer forms (Pollina et al. 1996). We 
agree, as in our studies expression correlated neither with clinical parameters 
nor with aggressive disease. Compared with works by others (Pilotti et al. 1994, 
Pollina et al. 1996, Basolo et al. 1997, Moore et al. 1998), the overall expression 
in our patient series was lower. This discrepancy may in part be explained by 
our use of different antibodies (Pilotti et al. 1994, Pollina et al. 1996, Basolo et 
al. 1997) or different cut-off values for positive expression (Pollina et al. 1996, 
Basolo et al. 1997, Moore et al. 1998). Our cut-off for positive expression was 
10%, in contrast to others who had lower cut-offs and reported higher positivity 
for bcl-2 (Pollina et al. 1996, Basolo et al. 1997, Moore et al. 1998). Ito et al. 
(2003) had the same antibodies and same cut-off as we did and expression was 
lowest 50.8% of all (Pollina et al. 1996, Basolo et al. 1997, Moore et al. 1998). 
Expression in our studies were 26% (Study III) and 35% (Study IV). 
MMP-2
In our series, increased stromal expression of MMP-2 correlated with advanced 
stage and with tumours extending beyond the thyroid capsule. Expression of 
MMP-2 in PTC has been shown to associate with large tumour size, high stage, 
high intrathyroidal invasion, capsular invasion, high vascular invasion, and 
lymph node metastasis (Maeta et al. 2001). Thus we conﬁ rmed some of these 
ﬁ ndings. Maeta et al. had 86 PTC cases in their immunohistochemical study, 
in which the ﬁ nal score was a combination of epithelial and stromal staining in 
tumour and in non-tumour tissue. Tumour cell expression was higher than in 
stromal cells. 
In our study, we analyzed epithelial and stromal staining separately. Similar to 
ﬁ ndings of Campo et al. (1992) and Zedenius et al. (1996), stromal staining was 
stronger than epithelial staining in contrast to other study (Maeta et al. 2001). 
Higher expression of MMP-2 in advanced stage and in extrathyroidal disease 
may relate to the poor outcome in our series. In matched pair patients, however, 
MMP-2 expression did not correlate with aggressive disease. Moreover, among 
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13 fatal cases, only 2 showed positive stromal staining; none of the fatal cases 
showed positive epithelial staining for MMP-2. In our study, the overall number 
of positive cases was similar to that of Nakamura et al. (1999), but lower than 
in other studies (Campo et al. 1992, Zedenius et al. 1996, Maeta et al. 2001). 
We cannot adequately explain this discrepancy: It may be attributable to the 
fact that we analyzed epithelial and stromal staining separately. Based on our 
observations, we would not consider MMP-2 to be a prognostic marker for PTC, 
as expression was quite low, and statistical signiﬁ cances were poor.
Correlation between COX-2 and MMP-2 agrees with previous results (Tsujii et 
al. 1997, Callejas et al. 2001, Dohadwala et al. 2002, Miyata et al. 2003). Tsujii 
et al. (1997) showed that in human colon cancer cells, activation of MMP-2 is 
modulated by COX-2. Dohadwala et al. (2002) reported that overexpression of 
COX-2 increases MMP-2 expression and facilitates invasion of lung cancer cells. 
A relationship has also been found between COX-2 and MMP-2 expression in 
foetal hepatocytes (Callejas et al. 2001). That study suggests that COX-2 is a 
key component in the secretion of MMP-2. Miyata et al. (2003) demonstrated a 
correlation between COX-2 and MMP-2 in patients with renal cell carcinoma in 
which expression of COX-2 correlated with high T, N, and M stage, high tumour 
grade, and expression of MMP-2. Furthermore, COX-2 inhibitors reduce colon 
cancer metastasis and MMP-2 production in animal models (Nagatsuka et al. 
2002, Yao et al. 2003). 
9.4 Non-published data 
Deaths from PTC have declined dramatically during the last few decades (Table 
6). Evidence that survival is longer for those patients treated after 1970 than for 
those treated earlier, deserves comment. In our opinion, increased use of total 
thyroidectomy and postoperative RAI ablation for PTC patients from the 1970s 
on might be the reason for better survival. Treatment factors have been shown to 
be as important as tumour biology in predicting tumour recurrence (Kouvaraki 
et al. 2004). Performing only lobectomy results in recurrences in the remnant 
thyroid lobe, a higher tumour recurrence rate, and higher incidence of distant 
metastases (Massin et al. 1984, Hay et al. 1987, Mazzaferri and Kloos 2001). 
Radioiodine therapy reduces recurrences and thyroid cancer-related mortality 
(Mazzaferri and Kloos 2001). 
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10.
Summary and Conclusions
The major ﬁ ndings were: 
• Age over 45, tumour size > 4 cm, extrathyroidal extension of tumour, 
nodal metastases, distant metastases, and stage IV disease correlated 
signiﬁ cantly with survival.
• TNM classiﬁ cation was more reliable than AMES or MACIS 
classiﬁ cations in predicting prognosis of PTC. TNM is the only 
staging method that takes into account lymph node metastases.
• Expression of COX-2, Ki-67, and VEGF-C was higher in older PTC 
patients, which could explain the more aggressive behaviour of PTC 
in the older age group. Most older lymph node-positive patients 
expressed VEGF-C and did not manage well. In contrast, most young 
lymph node-positive patients did not express VEGF-C and managed 
well, supporting the idea that older patients have different disease. 
• Expression of MMP-2, bcl-2, and p21 did not differ between young 
and older PTC patients. Stromal expression of MMP-2 correlated 
with extent of tumour and with advanced stage. In tumours extending 
beyond the thyroid capsule and in large tumours, p21 expression was 
higher. Bcl-2 expression did not correlate with clinical parameters. 
• In a series of matched pair groups (aggressive versus completely 
recovered), immunohistochemical expression of COX-2, MMP-2, bcl-
2, Ki-67, p21, and VEGF-C did not differ between groups, indicating 
that none of the markers could predict tumour behaviour. 
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• Immunohistochemically, expression of COX-2 and VEGF-C 
correlated strongly. In cell culture, this correlation was not so clear, 
because the COX-2 selective inhibitor NS-398 did not reduce VEGF-
C expression. However, because both COX-2 and VEGF-C were 
induced by tumour promoter (PMA), the same factors may control 
them both.
A tendency for improved outcomes of PTC patients over the past few years is a 
consequence of the increasing use of total thyroidectomy and 131I ablation, and 
most patients with papillary thyroid cancer can be cured if treated according to 
best clinical practice. 
In the present series of 601 PTC patients, all patients who died of PTC were 
over 45. Young age thus protects against cancer death in PTC. In older patients, 
PTC takes a more malignant course. Lymph node metastases are predictive for 
distant metastases and death in older patients, but not in younger ones. In young 
patients, PTC does not behave like most other types of cancer, as it does not 
cause death. 
Initial treatment and follow-up could possibly be individualized according to age. 
Older PTC patients, especially those with lymph node metastases, may beneﬁ t 
from more radical lymph node dissection and from more intensive follow-up. As 
COX-2 was elevated in older patients, there is a chance that these patients may 
also beneﬁ t from COX-2 selective inhibitors. However, serious cardiovascular 
side effects in clinical trials have reduced the excitement over using these drugs 
in chemoprevention. In PTC, COX-2 inhibitors could serve as adjuvant therapy, 
and in that setting, some side effects can be acceptable. 
Unexpectedly, also some young low-risk patients may suffer from aggressive 
disease. The problem is how to recognize these young patients from the large 
pool of patients who recover completely after primary treatment. Although we 
found elevated expression of COX-2, VEGF-C, and Ki-67 in those older, these 
three markers did not predict outcome, and thus we cannot use these proteins as 
tumour markers for predicting prognosis. Higher COX-2, VEGF-C, and Ki-67 in 
those older may only reﬂ ect the fact that PTC here is biologically different. Better 
understanding of differences in tumour biology at all ages may help us to choose 
those young patients who represent the tumour behaviour of older patients. 
To date, no ideal marker yet exists to predict the prognosis of the PTC patient. In 
future, identiﬁ cation of genetic variations that correlate with the poor prognosis 
may help us to focus on a subgroup with papillary thyroid cancer who will already 
beneﬁ t from more aggressive treatment at the onset of the disease. 
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